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PREFACE 
As the World Drug Report 2017 clearly shows, there 
is much work to be done to confront the many 
harms inflicted by drugs, to health, development, 
peace and security, in all regions of the world.
Globally, there are an estimated minimum of 
190,000 — in most cases avoidable — premature 
deaths from drugs, the majority attributable to the 
use of opioids.
The terrible impact of drug use on health can also 
be seen in related cases of HIV, hepatitis and 
tuberculosis. 
Much more needs to be done to ensure affordable 
access to effective scientific evidence-based preven-
tion, treatment and care for the people who 
desperately need them, including those in prison 
settings. As just one example, this year’s report high-
lights the need to accelerate accessibility to the 
treatment of hepatitis C, a disease whose negative 
health impact on people who use drugs is far greater 
than that of HIV/AIDS.   
Recent attention has focused on the threats posed 
by methamphetamine and new psychoactive sub-
stances (NPS). However, as the report shows, the 
manufacture of both cocaine and opioids is increas-
ing. These drugs remain serious concerns, and the 
opioid crisis shows little sign of stopping.
The World Drug Report 2017 further looks at the 
links with other forms of organized crime, illicit 
financial flows, corruption and terrorism. It draws 
on the best available evidence and, most of all, high-
lights the fact that much more research needs to be 
carried out in these areas. 
Corruption is the great enabler of organized crime, 
and opportunities for corruption exist at every stage 
of the drug supply chain. However, too little is 
known about how different types of corruption 
interact with drug markets. 
The outcome document of the special session of the 
General Assembly on the world drug problem and 
I am proud to say that this year we are marking 20 
years of the World Drug Report.
Over the past two decades, the United Nations 
Office on Drugs and Crime (UNODC) has been 
at the forefront of global research into complex areas 
of drug use and supply, supporting international 
cooperation and informing policy choices with the 
latest estimates, information on trends and 
analysis.
This year we are launching a new format, with the 
report available as five separate booklets: the execu-
tive summary, together with the report’s conclusions 
and policy implications; a global overview of drug 
use and supply; a market analysis of plant-based 
drugs; a market analysis of synthetic drugs; and a 
thematic booklet on the links between drugs and 
organized crime, illicit financial flows, corruption 
and terrorism. We have done this in response to 
readers’ needs and to improve user-friendliness, 
while maintaining the rigorous standards expected 
from the Office’s flagship publication. 
The 2017 report comes at a time when the interna-
tional community has acted decisively to achieve 
consensus on a way forward for joint action.
The outcome document unanimously adopted at 
last year’s special session of the General Assembly 
on the world drug problem contains more than 100 
concrete recommendations for implementing bal-
anced, comprehensive and integrated approaches to 
effectively addressing and countering the world drug 
problem. 
Moreover, at its sixtieth session, in March 2017,  the 
Commission on Narcotic Drugs adopted resolution 
60/1, reinforcing commitment to implementing the 
outcome document and charting a course to the 
2019 target date of the 2009 Political Declaration 
and Plan of Action on the world drug problem, as 
well as strengthening action towards the Plan of 
Action’s agreed goals and targets. 
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As the special session of the General Assembly and 
the recent session of the Commission on Narcotic 
Drugs have shown, the international community is 
equipped to respond swiftly and decisively to global 
drug-related challenges. 
For example, in March, the Commission scheduled 
two precursors and an analogue to the scheduled 
drug fentanyl. This important step will make it 
harder for criminals to illicitly manufacture fentanyl 
and its analogues and, I hope, can help to stem the 
tragic increase in opioid overdoses in recent years. 
However, there remains an enormous need for 
capacity-building and technical assistance, and fund-
ing continues to fall far short of political 
commitment. Further resources are urgently needed 
to help all Member States implement the recom-
mendations contained in the outcome document 
of the special session of the General Assembly and 
achieve related targets under the Sustainable Devel-
opment Goals.
The many evolving drug challenges also highlight 
the importance of prevention — science- and rights-
based drug use prevention — but also prevention 
of crime, corruption, terrorism and violent extrem-
ism, in line with commitments under the 
conventions and United Nations standards and 
norms. 
Finally, I ask all Governments to help us improve 
the evidence base for these reports. Areas such as 
the links between drugs, terrorism and insurgency 
clearly touch upon sensitive intelligence, and there 
are legitimate concerns about compromising sources, 
collection and operations. But if we want to effec-
tively address drug challenges we need to strengthen 
international cooperation and information-sharing 
to the extent possible, to close the gaps and ensure 
that joint action is targeted, effective and timely. 
Yury Fedotov
Executive Director
United Nations Office on Drugs and Crime
Security Council resolutions express concern about 
terrorist groups profiting from drug trafficking, 
among other forms of transnational organized crime.
It is well established that there are terrorists and 
non-State armed groups profiting from the drug 
trade — by some estimates, up to 85 per cent of 
opium poppy cultivation in Afghanistan is in terri-
tory under influence of the Taliban. 
However, evidence on the organized crime-terrorism 
nexus remains patchy at best. Moreover, these links 
are not static. Relations between organized crime 
and terrorists groups are always evolving, much like 
drug markets themselves.
As we have seen with the NPS market, drug use, 
supply, trafficking routes and the substances them-
selves continue to shift and diversify at alarming 
speed. 
Drugs continue to represent a major source of rev-
enue for organized crime networks, but business 
models are changing, with criminals exploiting new 
technologies, such as the darknet, that are altering 
the nature of the illicit drug trade and the types of 
players involved, with looser, horizontal networks 
and smaller groups becoming more significant. New 
ways of delivering drugs further point to the need 
to involve other sectors such as postal services in the 
fight against drug trafficking.   
Clearly, countries must be able to act and react to 
an ever-changing and formidable array of threats 
and problems. UNODC is fully engaged in strength-
ening responses, working closely with our United 
Nations partners and in line with the international 
drug control conventions, human rights instruments 
and the 2030 Agenda for Sustainable Development, 
which are themselves complementary and mutually 
reinforcing.
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EXPLANATORY NOTES 
The boundaries and names shown and the designa-
tions used on maps do not imply official endorsement 
or acceptance by the United Nations. A dotted line 
represents approximately the line of control in 
Jammu and Kashmir agreed upon by India and Paki-
stan. The final status of Jammu and Kashmir has 
not yet been agreed upon by the parties. Disputed 
boundaries (China/India) are represented by cross-
hatch owing to the difficulty of showing sufficient 
detail. 
The designations employed and the presentation of 
the material in the World Drug Report do not imply 
the expression of any opinion whatsoever on the 
part of the Secretariat of the United Nations con-
cerning the legal status of any country, territory, city 
or area, or of its authorities or concerning the delimi-
tation of its frontiers or boundaries.
Countries and areas are referred to by the names 
that were in official use at the time the relevant data 
were collected.
All references to Kosovo in the World Drug Report, 
if any, should be understood to be in compliance 
with Security Council resolution 1244 (1999).
Since there is some scientific and legal ambiguity 
about the distinctions between “drug use”, “drug 
misuse” and “drug abuse”, the neutral terms “drug 
use” and “drug consumption” are used in the World 
Drug Report.
All uses of the word “drug” in the World Drug Report 
refer to substances under the control of the inter-
national drug control conventions.
All analysis contained in the World Drug Report is 
based on the official data submitted by Member 
States to the United Nations Office on Drugs and 
Crime through the annual report questionnaire 
unless indicated otherwise.
The data on population used in the World Drug 
Report are taken from: United Nations, Department 
of Economic and Social Affairs, Population Divi-
sion, World Population Prospects: The 2015 
Revision. 
References to dollars ($) are to United States dollars, 
unless otherwise stated.
References to tons are to metric tons, unless other-
wise stated. R stands for the correlation coefficient, 
used as measure of the strength of a statistical rela-
tionship between two or more variables, ranging 
from 0 to 1 in case of a positive correlation or from 
0 to -1 in case of a negative correlation.  
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Expanding market for synthetic drugs 
Unlike the manufacture of heroin and cocaine, the 
manufacture of synthetic drugs is not geographically 
constrained, as the process does not involve the 
extraction of active constituents from plants that 
have to be cultivated in certain conditions for them 
to grow. Yet any analysis of the synthetic drugs 
market is complicated by the fact that information 
on synthetic drug manufacture is limited, which 
prevents the estimation of the volume of such drugs 
being manufactured worldwide. Nevertheless, data 
on seizures and use suggest that the supply of syn-
thetic drugs is expanding.
An increasing number of countries are reporting 
seizures of synthetic new psychoactive substances 
(NPS), with over 20 tons seized in 2015. Seizures 
of amphetamine-type stimulants (ATS) doubled in 
the five years prior to 2015, to reach 191 tons in 
2015. This was a result of sharp increases in the 
amounts of amphetamines seized, of which meth-
amphetamine accounted for some 61-80 per cent 
annually during that period. 
Methamphetamine accounts for  
considerable harm
Disorders related to the use of amphetamines 
account for a considerable share of the global burden 
of disease attributable to drug use disorders, second 
only to those related to the use of opioids. Available 
data show that, among amphetamines, metham-
phetamine represents the greatest global health 
threat. Methamphetamine use is spreading and an 
increasing number of methamphetamine users are 
seeking treatment. In addition to the established 
and expanding market for methamphetamine in 
East and South-East Asia and Oceania, there are 
growing concerns about methamphetamine use in 
North America, South-West Asia and parts of 
Europe. 
Geographical shift in the  
methamphetamine market
A major geographical shift appears to have occurred 
in the methamphetamine market in the last five 
years. In 2015, the quantity of methamphetamine 
intercepted in East and South-East Asia surpassed 
the quantity intercepted in North America for the 
first time, making East and South-East Asia the lead-
ing subregions for methamphetamine seizures 
worldwide. While this may be a reflection of an 
increase in the effectiveness of law enforcement in 
East and South-East Asia, methamphetamine traf-
ficking routes appear to be increasingly connecting 
previously unconnected markets in various subre-
gions. Of particular note is the large increase in 
methamphetamine seizures in China.
The expansion of the methamphetamine market in 
East and South-East Asia is visible in the, albeit 
scarce, information available on methamphetamine 
use and treatment. In 2015, experts in several coun-
tries in the subregion reported a perceived increase 
in the use of both crystalline methamphetamine and 
methamphetamine tablets. They also considered 
methamphetamine to be the most commonly used 
drug in some of those countries. In the same year, 
people receiving treatment for methamphetamine 
use accounted for the largest share of people treated 
for drug use in the majority of countries and terri-
tories in East and South-East Asia that reported on 
that indicator. 
In Oceania, there has been an increase in both the 
quantities of methamphetamine seized and the prev-
alence of its use.
Amphetamine trafficking expanding in 
Asia and Central America
In contrast to methamphetamine, amphetamine has 
been confined to fewer subregions, such as the Near 
and Middle East and Western and Central Europe. 
The quantities of amphetamine seized in 2015 point 
to a possible recent expansion of the amphetamine 
market in South-Eastern Europe, but this may be 
simply related to the large amphetamine market in 
the neighbouring Near and Middle East. Quantities 
of amphetamine seized also sharply increased in 
Central America and South-West Asia.
“Ecstasy” market becoming increasingly 
multifaceted
While smaller than the market for methampheta-
mine, the “ecstasy” market has grown in complexity 
and the variety of “ecstasy” products available to 
drug users has increased. The three main types are: 
(a) “ecstasy” tablets containing little or no MDMA 
KEY FINDINGS  
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A core group of over 80 NPS were reported every 
year during the period 2009-2015 and appear to 
have become established on the global market; a 
number of them have been placed under interna-
tional control. On the other hand, about 60 NPS 
seem to have disappeared from the market since 
2013. Problems in identifying them in a laboratory 
may be a factor, however, in the low level of report-
ing of these lesser-known substances. 
Use of synthetic cannabinoid products 
associated with severe health risks 
Synthetic cannabinoids are not simply synthetic 
versions of the substances occurring in herbal can-
nabis, as street names such as “synthetic cannabis” 
or “synthetic marijuana” may suggest. They are a 
diverse group of potent psychoactive compounds 
that are designed to mimic the desired effects of 
cannabis, of which there are also many new products 
on the market. Despite the predominance of syn-
thetic cannabinoids on the spectrum of NPS, users 
of cannabis have reported that they prefer natural 
cannabis to synthetic cannabinoids. 
There is growing recognition of the harm associated 
with intoxication resulting from the use of synthetic 
cannabinoids. While, in general, these health harms 
are not dissimilar to the intoxication caused by natu-
ral cannabis, the use of products containing certain 
synthetic cannabinoids has been associated with 
severe adverse health events including hospitalisa-
tions and fatalities. It cannot be concluded, however, 
that the untoward or undesirable effects of synthetic 
cannabinoids will limit their uptake or use.
Opioid market in a constant state of 
change 
The opioid market is becoming more diversified: 
this is illustrated by the example of the United States, 
where the opioid market comprises a combination 
of internationally controlled substances, particularly 
heroin, and prescription medicines that are either 
diverted from the legal market or produced as coun-
terfeit medicines on a large scale. These counterfeit 
medicines are made to look like pharmaceutical 
products while actually containing fentanyl and fen-
tanyl analogues, as well as non-opioid substances 
such as derivatives of benzodiazepine and 
methylphenidate. 
(3,4-methylenedioxymethamphetamine); (b) 
“ecstasy” tablets with an extremely high content of 
MDMA; and (c) “ecstasy” sold in powder or crystal 
form, under different street names. “Ecstasy” tablets 
with a high MDMA content are of particular con-
cern in Europe, where law enforcement entities have 
also discovered industrial-scale MDMA manufac-
turing facilities. 
New psychoactive substances potentially 
more lethal than other drugs, but market 
still relatively small
Despite the large number of NPS present in drug 
markets, the overall size of the market for such sub-
stances is still relatively small when compared with 
other drug markets. However, one of the most trou-
bling aspects of NPS is that users are unaware of the 
content and the dosage of the psychoactive sub-
stances contained in some NPS. This potentially 
exposes users of NPS to additional serious health 
risks. Little or no scientific information is available 
to determine the effects that these products may 
have and how best to counteract them. 
A number of NPS have been implicated in fatalities, 
while the injecting of NPS with stimulant effects 
has been reported among high-risk groups of people 
who use drugs, further aggravating the health risks 
to which people in those groups are exposed. 
New psychoactive substances continue to 
evolve, diversify and grow 
The NPS market continues to be very dynamic and 
is characterized by the emergence of large numbers 
of new substances belonging to diverse chemical 
groups. Between 2009 and 2016, 106 countries and 
territories reported the emergence of 739 different 
NPS to UNODC. 
Marketed in many different ways and forms, new 
substances often emerge quickly and disappear 
again, while some become used regularly among a 
small group of users. Several countries have reported 
NPS being sold under the name of controlled drugs 
such as “LSD” and “ecstasy”. Often used for reasons 
similar to those for the use of traditional drugs, their 
easy availability and low prices have made certain 
NPS highly attractive to some groups of drug users. 
A market for some NPS in their own right now 
appears to have been established.
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This booklet also contains the bulk of the analysis 
for the triennial global synthetic drugs assessment. 
With the emergence of NPS in traditional markets, 
the triennial assessment has analysed trends and 
significant developments in both the ATS market 
and emerging markets. An important aspect of the 
assessment is to highlight the links between the tra-
ditional ATS markets and emerging NPS markets. 
INTRODUCTION  
Although presented as a stand-alone publication, 
this booklet constitutes the fourth part of the World 
Drug Report 2017. The World Drug Report is aimed 
at improving the understanding of the world drug 
problem and contributing to fostering greater 
international cooperation for countering its impact 
on health, governance and security. The present 
booklet provides an extended analysis of the global 
synthetic drugs market, including of amphetamine-
type stimulants (ATS) such as amphetamine, 
methamphetamine and “ecstasy”, and of new 
psychoactive substances (NPS), as well as of GHB. 
Global  se izures
Global  number of  users
change from previous year
methamphetamine
132
tons
52
tons
amphetamine
6
tons
“ecstasy” synthetic NPS*
23
tons
methamphetamine
21%
amphetamine
8%
“ecstasy”
-35%
synthetic NPS
-39%
2015
37 million
use
rs
 of
 am
ph
eta
min
es and prescription sti mulants
22 million
“e
cs
tas
y” us
ers
2015
2015
* Excludes GBL, ketamine and other medicines.
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A.2. Methamphetamine: a dynamic 
global market
The transnational nature of global ATS trafficking 
routes has expanded, and they now connect subre-
gions that previously had independent markets, a 
trend that has been particularly evident in reports 
concerning methamphetamine.1 Between 2012 and 
2015, methamphetamine was reported to have been 
smuggled from a number of subregions, including 
Western and Central Africa, North Africa, North 
America, East and South-East Asia, the Near and 
Middle East/South-West Asia and Western and Cen-
tral Europe. East and South-East Asia and Oceania 
continue to be the main recipients of the metham-
phetamine trafficked worldwide, whereas the Near 
and Middle East, South-West Asia and Western and 
Central Europe appear to function primarily as tran-
sit points for global methamphetamine trafficking 
flows. In addition, there is a significant degree of 
intraregional methamphetamine trafficking occur-
ring in North America, Western and Central Europe 
and East and South-East Asia. 
1 UNODC, “Methamphetamine manufacture: global  
patterns and regional differences”, Global SMART Update 
2014, vol. 12 (September 2014).
A. AMPHETAMINE-TYPE 
STIMULANTS 
A.1. Amphetamine-type stimulants: 
market developments
Amphetamine-type stimulants (ATS) feature promi-
nently in drug markets worldwide, with global 
patterns of supply and demand, particularly for 
methamphetamine, becoming increasingly intercon-
nected and complex. In addition to the established 
and expanding market for methamphetamine in 
East and South-East Asia, there are growing con-
cerns about methamphetamine in North America, 
South-West Asia and in parts of Europe. Ampheta-
mine continues to feature prominently in synthetic 
drug markets in the Near and Middle East and in 
Western and Central Europe, and increasing seizures 
have recently been reported in parts of Central 
America, South-Eastern Europe and South-Western 
Asia. As ATS become increasingly available, concerns 
about the problems and health threats associated 
with ATS use are heightened, yet the quality of data 
and information on some aspects of the ATS market 
remains limited. In particular, information on ATS 
manufacture and demand-related data on the extent 
of ATS use remain scarce, which hinders estimates 
of the size of the ATS market. 
Seizures of amphetamine-type stimulants 
continue to increase
Seizure data suggest that ATS markets continued to 
increase globally from 2010 to 2015. Methampheta-
mine dominates the global ATS market, while 
amphetamine is the main substance in ATS markets 
only in selected subregions, particularly the Near 
and Middle East and West and Central Europe, and 
“ecstasy” accounts for a relatively small portion of 
the global ATS market. Overall, global quantities 
of ATS seized doubled from 93 tons in 2010 to 191 
tons in 2015, of which methamphetamine accounted 
for 61-80 per cent annually. With the exception of 
2012, global amphetamine seizures annually 
accounted for 20-32 per cent of global ATS seizures 
between 2010 and 2015, whereas “ecstasy” seizures 
annually accounted for less than 5 per cent of global 
ATS seizures over the same period. 
Fig. 1 Quantities of amphetamine-type  
stimulants seized worldwide, by type,  
2010-2015
Source: UNODC, responses to annual report questionnaire, 
2010-2015.
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Seizure data for the period 2010-2015 signalled a 
geographical shift, with 2015 seizures in East and 
South-East Asia accounting for the highest percent-
age of global seizures of methamphetamine and 
surpassing seizures in North America for the first 
time. The recent predominance of East and South-
East Asia in global seizures is possibly the result of 
two trends: methamphetamine markets expanding 
in Asia more than they are elsewhere, and an 
improved capacity of law enforcement authorities 
to detect methamphetamine, which is now recog-
nized as one of the major drug threats in the region. 
Of particular note is the large increase in metham-
phetamine seizures in China, which reached 37 tons 
in 2015. Other countries in East and South-East 
Asia, such as Myanmar and Thailand, have also seen 
a steady increase in annual seizure quantities, 
although their seizure levels remain lower than those 
of China.
Methamphetamine use is widespread and 
treatment demand is growing 
The expansion of the methamphetamine market in 
East and South-East Asia is visible in the — albeit 
Diverse forms of amphetamine-type stimulants
Methamphetamine, amphetamine and “ecstasy” are sold in 
illegal drug markets in a variety of forms. In East and South-East 
Asia, South-West Asia and North America, methamphetamine 
appears in two main forms: methamphetamine tablets and 
crystalline methamphetamine. Methamphetamine tablets, 
commonly known as “yaba” in East and South-East Asia, are 
small tablets of low purity that are available in many different 
shapes and colours and are commonly ingested or smoked 
after being crushed. Crystalline methamphetamine, also called 
“crystal meth”, “ice” or “shabu” (in East and South-East 
Asia), consists of (crushed) colourless crystals of various sizes 
and is usually of a much higher purity than the tablet form. 
In the case of crystalline methamphetamine, smoking, nasal 
insufflation and injecting are typical forms of use.a 
In the Near and Middle East, amphetamine tablets are typically 
labelled with the brand name “captagon”. Originally, “cap-
tagon” was the trade name of a pharmaceutical preparation 
containing fenetylline, a synthetic stimulant. However, in the 
past few years, most tablets seized as “captagon” essentially 
contained amphetamine, in combination with caffeine and 
occasionally with other adulterants.b 
In the Americas, Europe, East and South-East Asia and Oce-
ania, “ecstasy” is mainly available in tablet form. In addition, a 
niche market appears to have recently emerged for powder or 
crystalline MDMAc in some countries in Europe, North America 
and Oceania. In Australia, for example, the Ecstasy and Related 
Drugs Reporting System found that in 2015 more than half of 
the “ecstasy” users in that country had used “ecstasy” in the 
form of capsules containing powder or crystalline MDMA (60 
per cent of users) or in the form of MDMA “crystal/rock” (57 
per cent of users: an 18 per cent increase from the 2013 level), 
while tablets remained the form used by the vast majority of 
“ecstasy” users (82 per cent).d
a Terminology and Information on Drugs (United Nations publica-
tion, Sales No. E.03.XI.14); Recommended Methods for the Iden-
tification and Analysis of Amphetamine, Methamphetamine and 
Their Ring-Substituted Analogues in Seized Materials: Manual 
for Use by National Drug Testing Laboratories (United Nations 
publication, Sales No. E.06.XI.1).
b World Drug Report 2010 (United Nations publication, Sales 
No. E.10.XI.13), p. 114.
c MDMA (3,4-methylenedioxymethamphetamine) belongs to 
the “ecstasy”-group substances. It was placed under interna-
tional control in 1986 (Schedule I of the Convention on  
Psychotropic Substances of 1971).
d Jennifer Stafford and others, “The 2016 EDRS key findings: 
a survey of people who regularly use psychostimulant drugs”, 
EDRS Drug Trends Bulletin (Sydney, University of New South 
Wales, National Drug and Alcohol Research Centre, October 
2016).
Fig. 2 Quantities of methamphetamine seized 
worldwide, by region, 2010-2015
Source: UNODC, responses to annual report questionnaire, 
2010-2015.
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increased in recent years.6, 7 Although the share of 
people treated for crystalline methamphetamine use 
in Indonesia in 2014 was, at around 30 per cent, 
far smaller than in other countries in the subregion, 
this still signifies an increase of almost 20 per cent 
from the previous year. Moreover, in Malaysia, crys-
talline methamphetamine users accounted for 80 
per cent of ATS users receiving treatment in 2015, 
while the total number of ATS users receiving treat-
ment represented a 47 per cent increase since 2014.8 
In Oceania, quantities of methamphetamine seized 
increased in New Zealand from 15 kg in 2013 to 
0.4 tons in 2015 and in Australia from 2.3 tons to 
5.4 tons over the same period. Methamphetamine 
continues to be a drug of major concern in both 
countries. In Australia, data suggest that metham-
phetamine consumption has been increasing 
strongly in recent years,9 triggering a comprehensive 
government response.10
In North America, the current heroin and opioid 
epidemic may dominate the national drug threat, 
but the threat posed by methamphetamine remains 
a key concern. The results of the National Drug 
Threat Survey, conducted by the Drug Enforcement 
Administration (DEA) of the United States of Amer-
ica, in 2016, show that 31.8 per cent of responding 
law enforcement agencies in the United States iden-
tified methamphetamine as the greatest drug threat 
in their areas, meaning that methamphetamine is 
perceived to be the second greatest drug threat after 
heroin in that country. Moreover, the percentage of 
responding United States law enforcement agencies 
reporting high availability of methamphetamine has 
increased annually, from 39.5 per cent in 2013 to 
6 UNODC annual report questionnaire, replies submitted by 
the Philippines for 2010 to 2015.
7 Narcotics Division, Security Bureau, of Hong Kong, China, 
CRDA and Drug Statistics, 23 March 2017, “Newly/previ-
ously reported drug abusers by age group by common type 
of drugs abused (table 3)”. Available at www.nd.gov.hk/en/
statistics_list.htm.
8 The Drug Abuse Information Network for Asia and the 
Pacific.
9 Australian Criminal Intelligence Commission, National 
Wastewater Drug Monitoring Program Report (Canberra, 
March 2017).
10 Australia, Department of the Prime Minister and Cabinet, 
Final Report of the National Ice Taskforce 2015 (Canberra, 
2015).
scarce — information available on its use and treat-
ment. Experts in six countries in the subregion 
reported a perceived increase in the use in 20152 of 
both crystalline methamphetamine and metham-
phetamine tablets. In that same year, national experts 
considered methamphetamine to be the most used 
drug in China and Macao, China; Japan; the Phil-
ippines; and Singapore.3
In 2015, people receiving treatment for metham-
phetamine use accounted for the largest share of 
people treated for drug use in five of the seven coun-
tries and territories4 in East and South-East Asia 
that reported this indicator.5 In both the Philippines 
and Hong Kong, China, the number of people 
receiving treatment for methamphetamine use has 
2 These countries included Cambodia, China, Lao People’s 
Democratic Republic, Myanmar, Singapore and Viet Nam.
3 Drug Abuse Information Network for Asia and the Pacific.
4 These countries included Brunei Darussalam, the Lao Peo-
ple’s Democratic Republic, the Philippines, Singapore and 
Thailand.
5 The Drug Abuse Information Network for Asia and the 
Pacific.
Fig. 3 Number of persons treated for meth-
amphetamine use in the Philippines 
(2010-2015) and Hong Kong, China 
(2013-2015)
Sources: UNODC, responses to annual report questionnaire, 
2010-2015; Narcotics Division, Security Bureau, of Hong Kong, 
China. (See “Newly/previously reported drug abusers by age 
group by common type of drugs abused (table 3)”. Available 
at www.nd.gov.hk/en/statistics_list.htm).
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methamphetamine seizure quantities and seizures 
of clandestine methamphetamine laboratories have 
declined since 2013. A large increase in metham-
phetamine use was perceived in that country in 
2013; however, there is no recent information on 
prevalence of use trends, and it is not clear if and to 
what extent seizure trends reflect market 
developments.
Methamphetamine: trends in manufacture 
and precursors
Ephedrine and pseudoephedrine are two of the main 
precursors used in the manufacture of methamphet-
amine. Both chemicals have widespread legitimate 
use in the pharmaceutical industry, in bulk form 
and in the form of pharmaceutical preparations.15 
Historically, both ephedrine and pseudoephedrine 
in bulk form were the preferred precursors; however, 
because of increasingly strict controls in many coun-
tries, drug traffickers have diversified  their approach 
and also diverted pharmaceutical preparations 
target for research on blood-borne infection diseases”,  
Hepatitis Monthly, vol. 13, No. 2. (2013).
15 Precursors and Chemicals Frequently Used in the Illicit Manu-
facture of Narcotic Drugs and Psychotropic Substances: Report 
of the International Narcotics Control Board for 2014 on the 
Implementation of Article 12 of the United Nations Conven-
tion against Illicit Traffic in Narcotic Drugs and Psychotropic 
Substances of 1988 (E/INCB/2014/4).
45.4 per cent in 2016.11 Indeed, methamphetamine 
use in the United States continues to increase, with 
the annual prevalence of methamphetamine use 
among the general population aged 15-64 years 
rising from 0.5 per cent in 2012 to 0.8 per cent in 
2015. 
As well as persisting in regions such as Europe, where 
it has become consolidated in the past decades, the 
methamphetamine market is expanding into new 
geographical areas. Methamphetamine trafficking 
and use have emerged in Afghanistan, where, accord-
ing to the records of the Ministry of Public Health, 
908 methamphetamine users were registered at gov-
ernment treatment centres in Farah, Jawzjan, 
Kunduz and Nimroz provinces in the period 2011-
2012.12 In 2016, law enforcement agencies, 
health-care providers and treatment centres in cer-
tain parts of Afghanistan also perceived an increase 
in synthetic drug use, most of which was probably 
due to opiate users who also used methampheta-
mine. While the total annual quantity of 
methamphetamine seized in Afghanistan has, at less 
than 16 kg, remained quite small, the number of 
methamphetamine seizure reports in Afghanistan 
has increased. There are indications that some of 
the seized substance might have been manufactured 
domestically: a clandestine methamphetamine labo-
ratory was detected in Nimroz Province in 2013. 
However, there continue to be significant gaps in 
the information and data relating to synthetic drugs 
in Afghanistan, and overall treatment figures and 
the prevalence of methamphetamine use among the 
general population are not well understood.13
In other parts of South-West Asia, such as the Islamic 
Republic of Iran, the methamphetamine market has 
a longer history, and, as in Afghanistan, there are 
indications that methamphetamine is used among 
opioid users.14 In the Islamic Republic of Iran, both 
11 United States, Drug Enforcement Administration, 2016 
National Drug Threat Assessment Summary ( November 
2016).
12 Afghanistan, Ministry of Public Health, Drug Demand 
Reduction Department, “Monthly treatment records”, Hijri 
years 1390-1391 of the Islamic lunar calendar; Afghanistan, 
Ministry of Counter Narcotics, Afghanistan Drug Report 
2013, (December 2014).
13 UNODC, “Afghanistan synthetic drugs situation assess-
ment” (Vienna, January 2017).
14 Zahra Alam Mehrjerdi and Alireza Noroozi, “An emerg-
ing trend of methamphetamine injection in Iran: a critical 
Fig. 4 Quantity of methamphetamine seized  
and number of dismantled laboratories in  
the Islamic Republic of Iran, 2010-2015
Source: UNODC, responses to the annual report questionnaire 
from the Islamic Republic of Iran, 2010-2015.
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already mainly using phenylacetic acid and its esters 
in the manufacture of methamphetamine. In 2013, 
multi-ton seizures of phenylacetic acid were reported 
by China (6.5 tons) and Mexico (3.3 tons). The use 
of P-2-P-based methods seems to have expanded 
beyond Mexico, with seizures of P-2-P reported by 
Bulgaria in 201321 and Myanmar in 2014. Large 
seizures of P-2-P were also reported in 2014 by 
Mexico, China, Poland, Lithuania and the Nether-
lands (in descending order of seizure amounts), and, 
similarly, seizures were reported in 2015, with 
Mexico (more than 16,500 litres), Poland (almost 
7,000 litres) and China (almost 5,500 litres) being 
the most predominant. Notable seizure amounts 
were also reported that year by Myanmar22 (seizures 
of P-2-P) and Lebanon (16 tons of phenylacetic 
acid).23
Seizure data indicate that other chemicals that are 
not under international control may be used to 
manufacture methamphetamine and its precursors. 
Mexico has reported large seizures of ethyl 
phenylacetate: 520 kg and 12,000 litres in 2013 and 
63 tons in 2014. Notable seizures of other pre-
precursors included 8 tons of 2-phenylacetamide in 
Mexico and 10 tons of benzaldehyde in Australia in 
2013/14, although methamphetamine produced in 
Australia is primarily manufactured from ephedrine 
and pseudoephedrine.24 In 2015, Mexico also 
reported seizing more than 4,000 litres of 
benzaldehyde and almost 5,500 litres of 1-phenyl-
2-nitropropene (the product resulting from the 
reaction of benzaldehyde and nitroethane).25 
Profiling of methamphetamine seized in the United 
States in 2014-2015 reflected this by showing a 
significant increase in the use of benzaldehyde and 
nitroethane in the manufacture of P-2-P, which 
illustrates once again how drug trafficking 
organizations have adapted their approach in 
accordance with the availability of precursor 
chemicals.26 
21 E/INCB/2014/4.
22 Asia and Pacific Amphetamine-type Information Centre 
(APAIC), Synthetic drugs trends, National trends: Myan-
mar, 14 February 2017. Available at www.apaic.org.
23 E/INCB/2016/4.
24 Illicit Drug Data Report 2012-13, Illicit Drug Data Report 
2013-14 and Illicit Drug Data Report 2014-15. 
25 E/INCB/2016/4.
26 Ibid.; United States, Drug Enforcement Administration, 
containing ephedrine or pseudoephedrine. As dem-
onstrated in seizure data, 43 tons of the two 
precursors, in bulk form and 1 million tablets, were 
seized in 2013, with Australia, China, India, Mexico, 
Ukraine, the United Kingdom of Great Britain and 
Northern Ireland and the United States each report-
ing seizures greater than 1 ton. China alone reported 
a combined 16.7 tons of the two precursors seized 
in bulk form in 2013, 31.5 tons of bulk ephedrine 
in 2014 and 23.5 tons of that same precursor in 
2015. India also reported seizures of more than 10 
tons of ephedrine and 8.5 tons of pseudoephedrine 
in 2016.16 Other notable seizures of pharmaceutical 
preparations in South-East Asia include seizures 
totalling 3.5 tons of pharmaceutical preparations of 
pseudoephedrine in Myanmar in 2013. The trend 
is not always towards the use of pharmaceutical 
preparations. Indeed, in recent years Australia and 
New Zealand have reported decreasing seizure quan-
tities of preparations and increasing seizure quantities 
of ephedrine or pseudoephedrine in bulk form.17, 
18, 19, 20 
In order to circumvent controls on ephedrine and 
pseudoephedrine, traffickers started to use 1-phenyl-
2-propanone (P-2-P) as their most common 
alternative. The first country where this shift became 
apparent was Mexico, where traffickers shifted their 
manufacturing to the use of P-2-P, as well as to the 
pre-precursor phenylacetic acid, a precursor of P-2-P, 
and its derivatives. From 2009 to 2012, when 
Mexico still reported large seizures of P-2-P, profil-
ing data on methamphetamine from Mexico seized 
in the United States revealed that traffickers were 
16  Precursors and Chemicals Frequently Used in the Illicit Manu-
facture of Narcotic Drugs and Psychotropic Substances: Report 
of the International Narcotics Control Board for 2016 on the 
Implementation of Article 12 of the United Nations Conven-
tion against Illicit Traffic in Narcotic Drugs and Psychotropic 
Substances of 1988 (E/INCB/2016/4).
17 Precursors and Chemicals Frequently Used in the Illicit Manu-
facture of Narcotic Drugs and Psychotropic Substances: Report 
of the International Narcotics Control Board for 2015 on the 
Implementation of Article 12 of the United Nations Conven-
tion against Illicit Traffic in Narcotic Drugs and Psychotropic 
Substances of 1988 (E/INCB/2015/4).
18 Australian Crime Commission, Illicit Drug Data Report 
2012-13 (Canberra, April 2014).
19 Ibid., Illicit Drug Data Report 2013-14 (Canberra, May 
2015).
20 Ibid., Illicit Drug Data Report 2014-15 (Canberra, May 
2016).
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authorities in 2013 point to an expansion in the 
trafficking of amphetamine tablets labelled with the 
brand name “captagon”.28 According to the Turkish 
National Police, “captagon” seizures in 2013 mostly 
occurred in Turkish provinces such as Hatay and 
Gaziantep, located along the border with the Syrian 
Arab Republic. Turkish authorities suspect that 
amphetamine seizures in the country are linked to 
“captagon” trafficking in the Near and Middle East, 
for which Turkey functions as both a transit and 
destination country. For instance, in 2013, Turkish 
authorities found that a consignment of “captagon” 
seized in Hatay Province had been manufactured in 
the Syrian Arab Republic and was destined for the 
Arabian Peninsula, with Turkey as a transit 
country.29
28 See box on page 15.
29 European Monitoring Centre for Drugs and Drug Addic-
tion, 2014 National Report (2013 Data) to the EMCDDA by 
the Reitox National Focal Point: Turkey − New Development, 
Trends and In-Depth Information on Selected Issues (Ankara, 
Turkish Monitoring Centre for Drugs and Drug Addiction, 
2014).
A.3. Amphetamine trafficking is 
spreading
In contrast to methamphetamine, amphetamine has 
been confined to fewer subregions, and seizures show 
stabilizing trends at the global level. Amphetamine 
has long been a prominent feature of synthetic drug 
markets in the Near and Middle East and Western 
and Central Europe, but there are signs of increas-
ing seizures in South-Eastern Europe, which is 
mainly related to the large amphetamine market in 
the neighbouring Near and Middle East. From very 
low levels, quantities of amphetamine seized in Cen-
tral America have increased greatly since 2014, but 
the reasons for this development remain unclear. 
In the Near and Middle East, amphetamine con-
tinues to be extensively trafficked on an intraregional 
basis. In 2013 and 2014, amphetamine was primar-
ily reported to have been trafficked within the 
subregion from Jordan, Lebanon and the Syrian 
Arab Republic to countries such as Israel, Jordan, 
Qatar, Saudi Arabia and the United Arab Emirates. 
However, recent seizure reports indicate that coun-
tries outside the region are also feeding the 
amphetamine market in the Near and Middle 
East.27 It remains to be seen whether these new 
reports of amphetamine trafficking from outside 
the subregion indicate the development of new 
routes. 
Recently, a large increase in amphetamine seizures 
has been reported in South-Eastern Europe, which 
may be related to the expansion of amphetamine 
trafficked in the neighbouring Near and Middle 
East. In 2015, the amount of amphetamine seized 
in South-Eastern Europe accounted for an 8 per 
cent share of global amphetamine seizures, increas-
ing from less than 0.5 tons of amphetamine seized 
in 2014 to almost 4 tons in 2015. The increase in 
amphetamine seizures in South-Eastern Europe is 
primarily due to the increase in seizures reported in 
Turkey, which went up from 0.2 tons in 2014 to 
3.8 tons in 2015. Although further information on 
the amphetamine situation in Turkey is not avail-
able for those years, earlier reports from the national 
2016 National Drug Threat Assessment Summary.
27 Individual drug seizures reported to UNODC for the 
period 2014-2015 and drug seizures reported in the media 
from March 2014 to November 2015. 
Fig. 5 Quantities of amphetamine seized 
worldwide, by region, 2010-2015
Source: UNODC, responses to annual report questionnaire, 
2010-2015.
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with the exception of those in Belgium, Poland and 
Sweden, where some were also medium-sized. P-2-P 
is the primary precursor used for the manufacture 
of amphetamine in Europe, and in recent years the 
emergence of a pre-precursor to P-2-P, namely alpha-
phenylacetoacetonitrile (APAAN), has been seen in 
a number of countries. Since its international 
scheduling in 2013, increased seizures of APAAN 
have been reported, including 5.4 tons in Belgium, 
more than 1 ton in Estonia and 180 kg in Lithuania. 
A total of 43.5 tons were seized in 2013, and while 
seizures decreased in 2014, 11 tons of the substance 
were seized, including 5.1 tons seized in Germany, 
3 tons seized in the Netherlands and 2 tons seized 
in Bulgaria. Seizures of APAAN continued to 
decrease in 2015, with slightly more than 1.5 tons 
in total being reported by five countries.32 
There has been a recent surge in amphetamine sei-
zures in Central America. In 2015, around 25 per 
cent of global amphetamine seizures were in that 
region, increasing from 1.5 tons in 2014 to 12.7 
tons in 2015. This large increase in amphetamine 
seizures is almost entirely attributable to the increase 
32 E/INCB/2015/4.
The manufacture and trafficking of amphetamine 
in Western and Central Europe is intraregional and 
amphetamine constitutes the most important ATS 
in terms of quantities seized. In 2015, countries in 
that subregion identified only countries within the 
same subregion as the origin of their amphetamine 
seizures, with six countries reporting the Nether-
lands as a country of origin and five reporting 
Poland.30
Amphetamine manufacture has been reported in a 
number of countries in Europe. In the period 2014-
2015, amphetamine laboratories were discovered in 
Austria, Belgium, Germany, Hungary, Latvia, the 
Netherlands, Poland, Spain and Sweden. The largest 
number of amphetamine laboratories dismantled 
was in Belgium (14) and in Germany (13), but the 
Netherlands also reported a large number of 
laboratories dismantled.31 Most amphetamine 
laboratories discovered in Western and Central 
Europe in the period 2014-2015 were small-scale, 
30 These countries include Austria, Czechia, Denmark, Poland 
and Sweden.
31 The Netherlands reported the dismantling of a total of 59 
“ecstasy”/amphetamine laboratories in 2015. Disaggregated 
figures by manufactured drug were not available. 
Map 2 Amphetamine and "captagon" trafficking flows with countries in the Near and Middle East 
reported as provenance or destination, 2014-2015
Source: UNODC, responses to annual report questionnaire, 2014-2015, and official communication.
Note: The origins of the flow arrows do not necessarily indicate the source/manufacture of amphetamine/"captagon". Flow arrows  
represent the direction of trafficking and are not an indicator of the quantity trafficked. The boundaries shown on this map do not imply 
official endorsement or acceptance by the United Nations. Dashed lines represent undetermined boundaries. The dotted line represents 
approximately the Line of Control in Jammu and Kashmir agreed upon by India and Pakistan. The final status of Jammu and Kashmir has 
not yet been agreed upon by the parties. The final boundary between the Sudan and South Sudan has not yet been determined.
WESTERN AND 
CENTRAL EUROPE
NORTHERN
AFRICA
NORTH
AMERICA
ASIA
Countries in
the Gulf regions
unspecified
Flows mentioned by countries of 
origin/departure, transit or destination
Saudi 
Arabia
Bahrain
Kuwait
Turkey
Jordan
Syrian Arab 
Republic
UAE
Qatar
Israel
Lebanon
Source: Individual drug seizures reported to UNODC in 2014/2015 and drug seizures reported in the media in March 2014-November 2015. 
Note: The trafficking  flows are determined on the basis of country of origin/departure, transit and destination of seized drugs: as such, they need to be considered as broadly indicative of existing trafficking routes while several 
secondary flows may not be reflected. Flow arrows represent the direction of trafficking: origins of the arrows indicate either the area of manufacture or the one of last provenance, end points of arrows indicate either the area of 
consumption or the one of n xt destination of tra fi king.
The boundaries shown on this map do not imply official endorsement or acceptance by the United Nations. Dashed lines represent undetermined boundaries. The dotted line represents approximately the Line of Control in Jammu 
and Kashmir agreed upon by India and Pakistan. The final status of Jammu and Kashmir has not yet been agreed upon by the parties. The final boundary between the Sudan and South Sudan has not yet been determined.
Destinati n country may not be final destination of seized shipment. Arrows represent individual cases, not routes or flows.
Trafficking flows of amphetamine/Captagon affecting countries in the Middle East as origin or destination, 2014/2015
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Amphetamine and methamphetamine: trends in manufacture 
The illicit production of synthetic drugs, by nature, requires 
the use of precursor chemicals. In general, the clandestine 
manufacture and production of such substances is highly 
flexible, and a wide range of precursor chemicals can be used. 
Detected trends in the precursor chemicals used in the illicit 
manufacture of synthetic drugs provide important information 
that contributes to a more comprehensive understanding 
of synthetic drug markets, particularly for law enforcement 
authorities, forensic scientists and customs personnel in their 
respective roles in tackling the global trade in illicit drugs. The 
figure below shows the different substances that are typically 
used to manufacture amphetamine and methamphetamine, 
differentiating those that are not under international control. 
This helps understanding of how drug trafficking organi-
zations attempt to modify their approaches and alter their 
manufacturing methods in response to national/international 
control and the efforts of law enforcement and industry in 
targeting and preventing the diversion of chemicals.
that amphetamine seized in Central America is sig-
nificantly connected to the North American 
amphetamine market. For example, Mexico has 
identified El Salvador only once as a departure coun-
try for amphetamine seized — in 2013. 
A.4. “Ecstasy”
“Ecstasy” products are increasingly  
diversified
“Ecstasy” is a term that has traditionally been used 
to describe tablets containing 3,4-methylenediox-
ymethamphetamine (MDMA). In the past decade, 
however, the “ecstasy” market has undergone major 
reported in Guatemala, where national authorities 
have reported amphetamine manufacture. Between 
2013 and 2015, Guatemala reported having dis-
mantled four or five amphetamine laboratories 
annually. However, the trafficking routes for the 
amphetamine manufactured in Central America 
remain unclear. In 2014 and 2015, Guatemala per-
ceived Honduras and El Salvador to be the 
provenance of the amphetamine seized domestically, 
yet there are no indications of an expanding domes-
tic market for amphetamine in Guatemala. Although 
large amounts of amphetamine have also been seized 
in North America, there are no clear indications 
Precursors for amphetamine and methamphetamine
Source: UNODC, Laboratory and Scientific Section.
Not under international control
Under international control (Table 1, 1988 Convention)
Under international control (Schedule II, 1971 Convention)
phenylacetic
 acid
1-phenyl-2-propanone  
 (P-2-P) 
ephedrine/
 pseudoephedrine
alpha-phenylacetoacetonitrile 
 (APAAN)
esters of 
phenylacetic 
acid
Benzal-
dehyde
amphetamine
norephedrine
methamphetamine
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changes and has grown in complexity. Available 
products branded as “ecstasy” are now increasingly 
diversified, the three main types being “ecstasy” tab-
lets containing little or no MDMA, “ecstasy” tablets 
with an extremely high content of high-purity 
MDMA, and “ecstasy” sold in powder/crystal form, 
under different street names.
Sales of tablets branded as “ecstasy” containing little 
or no MDMA have surged worldwide since a global 
plunge in MDMA supply towards the end of the 
previous decade following large seizures of precur-
sors. These tablets often contain adulterants/
substitutes, including a range of NPS, some of which 
have proved dangerous (see box). The reaction of 
consumers to the sale of adulterated/substituted 
“ecstasy” tablets has possibly led to the creation of 
a market niche for “ecstasy” in powder/crystal form, 
which is considered by users to contain MDMA of 
high purity (although powder is actually easier to 
adulterate than other forms and nowadays often 
contains NPS).33, 34 User preference for powder or 
crystalline MDMA remains a regional phenomenon, 
but it is particularly prominent in North America, 
Western and Central Europe and Oceania. 
In recent years, the market has seen the emergence 
of “ecstasy” tablets with a much higher content of 
MDMA than in the past, which tend to have very 
distinct shapes, colours and logos, most likely for 
branding purposes. This phenomenon has been 
linked to the apparent recovery of the “ecstasy” 
market (in terms of increased supply, use and 
improved quality of available products) seen in 
recent years, particularly in Europe.35
Manufacture and trafficking of “ecstasy” 
are spreading to other regions
According to the European Monitoring Centre for 
Drugs and Drug Addiction (EMCDDA) and the 
European Police Office (Europol), the Netherlands 
33 Joseph J. Palamar, “There’s something about Molly: the 
underresearched yet popular powder form of ecstasy in the 
United States”, Substance Abuse, vol. 38, No. 1 (2017). 
34 Claudio Vidal Giné and others, “Crystals and tablets in the 
Spanish ecstasy market 2000-2014: are they the same or 
different in terms of purity and adulteration? Forensic  
Science International, vol. 263 (2016), pp. 164-168. 
35 EMCDDA, Recent Changes in Europe’s MDMA/Ecstasy 
Market: Results from an EMCDDA Trendspotter Study, 
EMCDDA Rapid Communication Series (Luxembourg, 
Publications Office of the European Union, 2016).
and Belgium are the most important areas for 
MDMA manufacture in Europe, where the profes-
sionalism of manufacturing facilities is increasing.36 
The manufacture of “ecstasy” is also occurring in 
other regions and subregions, including Asia, North 
America, Oceania and South America. 
Annual “ecstasy” seizures have averaged around 4-5 
tons since 2010, except for a peak in 2014 when 
they reached 9 tons. The 2014 peak can be explained 
by unusually large seizures in Australia, which 
exceeded 4 tons, as well as the more than 700 kg of 
36 EMCDDA and Europol, EU Drug Markets Report:  
In-Depth Analysis, Joint Publications Series (Luxembourg, 
Publications Office of the European Union, 2016).
PMMA sold as “ecstasy”, with 
deadly consequences
One example of adulterated “ecstasy” are tab-
lets containing para-methoxymethamphetamine 
(PMMA), an MDMA substitute with a slower onset 
of action than other forms, which does not pro-
duce the same euphoric/empathogenic effects. 
Unsuspecting users ingesting PMMA-adulterated 
tablets may assume that the dose is too low and take 
greater amounts, which may lead to intoxication. 
PMMA has been associated with fatalities in several 
European countries, the first of which occurred in 
Spain in 1993,a and later in Canada.b Since 2009, 
the sale of PMMA-adulterated “ecstasy” tablets 
has intensified and seems to endure (PMMA has 
been reported in Australia, Belgium, Brunei Darus-
salam, Bulgaria, Colombia, Croatia, Estonia, Finland, 
France, Greece, Indonesia, Ireland, Israel, Italy, Japan, 
the Netherlands, Norway, Poland, the Republic of 
Korea, Romania, the Russian Federation, Singapore, 
Slovakia and Spain, and Hong Kong, China).c In 
2016, PMMA was linked with five deaths in Argen-
tina, and the Trimbos Institute issued a red alert after 
pink “Superman” pills containing PMMA reappeared 
in the Netherlands.d 
a EMCDDA, Report on the Risk Assessment of PMMA 
in the Framework of the Joint Action on New Synthetic 
Drugs (Luxembourg, Publications Office of the Euro-
pean Union, 2003). 
b Jennifer J. E. Nicol and others, “Deaths from  
exposure to paramethoxymethamphetamine in 
Alberta and British Columbia, Canada: a case series”, 
CMAJ Open, vol. 3, No. 1 (2015), pp. E83-E90. 
c UNODC early warning advisory on new psycho-
active substances. 
d For further information, see www.trimbos.nl.
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to the Canadian and Mexican borders, indicating 
the hub-like or source-like status of those cities.37 
Developments in regional “ecstasy”  
markets
The European “ecstasy” market seems to be expand-
ing. Evidence of this are the industrial-scale MDMA 
manufacturing facilities being encountered by law 
enforcement agencies, increasing quantities of 
“ecstasy” being seized, increasing trends in the use 
of “ecstasy”, aggressive marketing and branding, and 
growing concerns over “ecstasy” tablets with high 
MDMA content. The market for “ecstasy” in Europe 
is estimated to be worth at least 0.67 billion euros 
per annum.38 European “ecstasy” seizures increased 
from 2013 to 2015, reaching almost 4 tons, while 
recent surveys indicate an overall increase in the use 
of “ecstasy” in Europe.39
“Ecstasy” has a strong presence in the North 
American market. While use is stable, increasing 
MDMA purity in “ecstasy” products is an indication 
that the market is recovering. In recent years, several 
facilities manufacturing MDMA have been 
dismantled in Canada and the United States. Canada 
has reported a large increase in “ecstasy” use, with 
the estimated number of users rising from about 
100,000 in 2014 to over 200,000 in 2015. The 
prevalence of “ecstasy” use in the United States 
seems, however, to have remained stable between 
2013 and 2015, with the number of users estimated 
at around 2.5 million. Data collected on the 
composition of street “ecstasy” tablets in the United 
States indicate a strong decrease in “ecstasy” tablet 
adulteration between 2009 and 2016, with MDMA 
being the only psychoactive component in almost 
half of “ecstasy” tablets tested in 2016 (a dramatic 
increase in MDMA content compared with the 
corresponding figure of 8.7 per cent in 2009).40 In 
particular, there has been a dramatic drop in the 
number of tablets containing stimulant adulterants. 
37 Siddharth Chandra, Yan-Liang Yu and Vinay Bihani, “How 
MDMA flows across the USA: evidence from price data”, 
Global Crime, vol. 18, No. 2 (2016).
38 EMCDDA and Europol, EU Drug Markets Report:  
In-Depth Analysis.
39 EMCDDA, European Drug Report: Trends and Developments 
2016. (Luxembourg, Publications Office of the European 
Union, 2016).
40 For further information, see www.ecstasydata.org/stats.php.
“ecstasy” pills seized in Myanmar that same year. In 
2015, quantities of “ecstasy” intercepted fell to 6 
tons, with Europe accounting for almost 4 tons and 
Asia, the Americas and Oceania each accounting for 
less than 1 ton.
Data on dismantled facilities manufacturing 
“ecstasy”, together with seizure statistics, suggest 
trafficking dynamics that originate mainly in West-
ern and Central Europe. East and South-East Asia 
is a major destination for consignments originating 
in Europe or North America, with certain countries 
appearing to be important transit points. Oceania 
is on the receiving end of extensive “ecstasy” traf-
ficking from Europe, either directly or through East 
and South-East Asia. The Americas are an important 
destination for consignments from Europe, with 
North America also being the origin of shipments 
destined for East and South-East Asia (see map 3). 
Further insight into MDMA trafficking flows in 
North America has been provided by a recent study 
that used wholesale prices of MDMA in 59 cities 
in the United States to infer trafficking patterns. 
The analysis identified low prices in cities adjacent 
Fig. 6 Number of seized facilities related to the manu-
facture of “ecstasy”, 2013-2015
Source: UNODC, responses to annual report questionnaire, 2013-2015. 
Note: Data consist mostly of dismantled manufacturing sites; a small number 
of storage facilities and dumping sites were also reported and included in the 
figure.
a The Netherlands reported the seizure of a total of 59 “ecstasy”/amphetamine 
laboratories in 2015. Disaggregated figures by manufactured drug were not 
available.
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The trafficking of “ecstasy” to North America 
appears to be on the increase. In 2015, the number 
of seizures of MDMA trafficked to Canada increased 
by 109 per cent from the previous year, and the 
quantities increased by 513 per cent (throughout 
2015, trafficking activities targeting Canada from 
the Netherlands increased significantly). Canada is 
known as a source and transit country for MDMA 
destined for the United States and other interna-
tional markets, and Asian organized criminal groups 
are active in the cross-border smuggling of large 
quantities of MDMA between Canada and the 
United States as well as in the importation of pre-
cursor chemicals from source countries such as 
China, India and Viet Nam. 
Data on the development of the “ecstasy” market 
in Latin America remain limited. According to the 
Inter-American Drug Abuse Control Commission 
(CICAD), “ecstasy” is the most widely used ATS in 
Latin America (and in the Americas as a whole), 
although its market share still seems to be relatively 
low compared with that of other drugs under inter-
national control. In some countries there is great 
concern over the use of “ecstasy” at a very young 
age, among secondary school students.41 A study 
on the composition of “ecstasy” tablets in Brazil, 
conducted on samples from 150 different seizures 
made by Sao Paulo State Police (from August 2011 
to July 2012) documented a strong trend in tablet 
adulteration; one particularly surprising result was 
the presence of methamphetamine in 22 per cent 
of the tablets analysed.42 Seizures of “ecstasy”-type 
substances are generally low in Latin America. How-
ever, Brazil reported considerable amounts seized in 
2014 (238 kg) and 2015 (153 kg). In Argentina, a 
record amount (180 kg) of “ecstasy” was seized in 
2014, compared with only 20 kg in 2015. Chile 
and Colombia reported “ecstasy” seizures exceeding 
30 kg, which was a dramatic increase from 2014, 
when only 2 kg were seized in Chile and 5 kg were 
seized in Colombia. 
41 Inter-American Drug Abuse Control Commission of the 
Organization of American States, Report on Drug Use in the 
Americas, 2015 (Washington D.C., 2015). 
42 Loraine R.Togni and others, “The variability of ecstasy tab-
lets composition in Brazil”, Journal of Forensic Sciences, vol. 
60, No. 1 (2015), pp.147-151.
Oceania is an increasingly important market for 
“ecstasy”. In Australia, according to the Ecstasy and 
Related Drugs Reporting System, pills remain the 
most popular form of “ecstasy” consumed regularly. 
However, the trend in the use of MDMA crystal 
(also known in Australia under the street name 
“rock”), first recorded in 2013, continues to increase. 
This form of MDMA is perceived to be more pure 
and potent than pills, powder and capsules, as 
reported by 54 per cent of MDMA crystal users. All 
forms of “ecstasy” were reported as being “easy” to 
“very easy” to obtain, and prices remained stable at 
about 25 Australian dollars per pill, 30 Australian 
dollars per capsule and 200 Australian dollars per 
gram of crystal MDMA.43 Australia reported record 
“ecstasy” seizures in 2014, which exceeded 4 tons; 
however, seizures reported in 2015 amounted to less 
than 700 kg. Another recent development is the 
trafficking of MDMA in masked form as N-tert-
butoxycarbonyl-MDMA. In September 2015, 80 
litres of this substance were seized by the Australian 
Border Force.44 In New Zealand, yearly seizures of 
“ecstasy” have been fluctuating between 5 and 50 
kg since 2010.
In East and South-East Asia, many countries report 
seizures and use of “ecstasy”; however, pills sold as 
“ecstasy” in these areas may contain substances other 
than MDMA. Singapore reported an “ecstasy” purity 
of 36 per cent in 2015, a significant increase 
compared with the figures reported in the five 
preceding years (a range of 15.7-24.2 per cent). The 
retail price of “ecstasy” in Singapore has remained 
stable over the past five years at between 
approximately $18 and $22 per pill.45 Further 
research is required to understand whether that steep 
increase in purity while prices remained stable 
indicates a greater availability of MDMA, as 
observed in other subregions. 
43 Jennifer Stafford and others, “The 2016 EDRS key find-
ings: a survey of people who regularly use psychostimulant 
drugs”, EDRS Drug Trends Bulletin (Sydney, University of 
New South Wales, National Drug and Alcohol Research 
Centre, October 2016).
44 Michael Collins and others, “Identification and characteri-
zation of N‐tert‐butoxycarbonyl‐MDMA: a new MDMA 
precursor”, Drug Testing and Analysis, vol. 9, No. 3 (2016). 
45 APAIC, Synthetic drug trends, National trends: Singapore, 
1 December 2014. Available at www.apaic.org. 
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Certain countries in the subregion seem to be 
involved in the trafficking of “ecstasy” or MDMA 
precursors. The large “ecstasy” seizure made in 
Myanmar in 2014 raised questions about the level 
of trafficking in that country and its role as a transit 
point. Before and after 2014, Myanmar reported 
insignificant quantities of “ecstasy” seized, but in 
2014 itself a total of nearly 2.4 million “ecstasy” 
pills containing MDMA were seized in one single 
case, off the coast of Tanintharyi.46 The seized pills 
were destined for Malaysia, which has been per-
ceived to be a transit country for “ecstasy” by several 
countries, including Brunei Darussalam, New Zea-
land and Singapore, in recent years. Large quantities 
of “ecstasy” pills have also been seized in Malaysia 
in recent years, with some 408,000 “ecstasy” pills 
being seized in the country in 2015. Transnational 
drug trafficking groups are increasingly targeting 
Malaysia as both a destination and transit country 
for methamphetamine and other illicit drugs, as well 
as for the manufacture of MDMA to produce 
46 APAIC, Synthetic drug trends, National trends: Myanmar, 
14 February 2017. Available at www.apaic.org.
“ecstasy” pills.47 Indonesia reported significant 
annual seizure amounts in the period 2010-2015, 
which oscillated between 0.1 tons and 1.3 tons. In 
Cambodia, the national authorities have made sev-
eral significant seizures of precursor chemicals 
related to ATS manufacture in recent years. In par-
ticular, safrole-rich oils, one of the key precursor 
chemicals used in the manufacture of “ecstasy”, con-
tinue to be produced in the country and trafficked 
to other countries and regions, including Europe. 
For instance, in August 2014, approximately 5,220 
kg of safrole-rich oils was found by the police buried 
underground in Pursat Province, near the Gulf of 
Thailand in the western part of the country. A fur-
ther 110 litres of safrole-rich oils were reported 
seized in the same province in May 2016.48
Recent trends in “ecstasy” precursors 
A number of precursor chemicals are commonly 
used for the manufacture of “ecstasy”-group 
47 APAIC, Synthetic drug trends, National trends: Malaysia, 
14 February 2017. Available at www.apaic.org.
48 APAIC, Synthetic drug trends, National trends: Cambodia, 
14 February 2017. Available at www.apaic.org.
Fig. 7 Precursors for “ecstasy”-type substances
Source: UNODC, Laboratory and Scientific Section.
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and Spain in 2014-16 (INCB).54, 55, 56 Given that 
3,4-MDP-2-P methyl glycidate can be manufac-
tured from piperonal,57 it is likely that this 
transformation is being carried out by drug traffick-
ing organizations to mask controlled precursors and 
bypass national and international controls. 
B. NEW PSYCHOACTIVE  
SUBSTANCES AND OTHER 
SYNTHETIC DRUGS
B.1. New psychoactive substances: 
market developments
New psychoactive substances (NPS) are substances 
of abuse that have similar effects to drugs under 
international control such as cannabis, cocaine, 
heroin, (+)-lysergide (LSD), MDMA (“ecstasy”) and 
methamphetamine. A phenomenon reported by an 
increasing number of countries from 2009 onwards, 
this has since become a truly global issue, with over 
100 countries and territories in all regions having 
reported the emergence of NPS. 
Indeed, NPS are proliferating at an unprecedented 
rate and pose a significant risk to public health and 
a challenge to drug policy. More information on the 
prevalence of use of NPS has become available in 
recent years, ranging from representative population-
based surveys among the general population or 
youth to qualitative, small-scale studies among spe-
cific user groups such as homeless persons or persons 
in prison settings. While the availability of more 
information on the prevalence of NPS use suggests 
that NPS use could be spreading, the increase may 
be partly due to improved survey instruments, which 
capture NPS use better than before, and increased 
research interest in the topic. That said, an overall 
assessment of NPS use and use trends remains dif-
ficult. More evidence continues to emerge about 
the harmful effects of NPS use, some of which is 
presented in this report (see the chapter on synthetic 
54 E/INCB/2014/4.
55 E/INCB/2015/4.
56 E/INCB/2016/4. 
57 Michael Collins and others, “Methyl 3-[3’,4’-(methylenedi-
oxy)phenyl]-2-methyl glycidate: an ecstasy precursor seized 
in Sydney, Australia”, Journal of Forensic Science, vol. 52, 
No. 4 (2007), pp. 898-903. 
substances, which are controlled under the United 
Nations Convention against Illicit Traffic in Nar-
cotic Drugs and Psychotropic Substances of 1988. 
Of these, piperonal, safrole (including in the form 
of safrole-rich oils) and isosafrole are used in the 
chemical and pharmaceutical industries and are thus 
susceptible to diversion from licit trade. The other 
most common precursor is 3,4-methylenedioxyphe-
nyl-2-propanone (3,4-MDP-2-P or PMK), which 
itself has little or no legitimate use. Seizures of these 
precursors have fluctuated in recent years, with sei-
zures of 3,4-MDP-2-P reported by Belgium (2,700 
litres) and Slovenia (900 litres), and the Netherlands 
reporting the seizure of 14,000 litres of safrole-rich 
oils, in 2013. By contrast, significantly smaller sei-
zures were reported later in the period 2014-2015, 
although notable amounts were seized by Namibia 
(2,100 litres of isosafrole) and Canada (1,500 litres 
of safrole-rich oils).49, 50, 51
The most notable development in the area of pre-
cursors for “ecstasy”-group substances in recent years 
parallels the situation with methamphetamine man-
ufacture, in that drug traffickers appear to be using 
increasing amounts of non-controlled pre-precursor 
chemicals. In particular, the methyl glycidate ester 
and sodium glycidic salt of 3,4-MDP-2-P have been 
reported by a number of countries in the last two 
to three years. The identification of 3,4-MDP-2-P 
methyl glycidate in the clandestine manufacture of 
“ecstasy”-group substances was first identified in the 
Netherlands in 2010.52 In recent years, large 
amounts of variants of 3,4-MDP-2-P methyl glyci-
date have been seized, with Slovenia (1.2 tons) and 
China (1.5 tons) reporting seizures of 3,4-MDP-2-P 
glycidic acid in 2013. Seizures of the methyl ester 
or sodium salt of 3,4-MDP-2-P totalling an equiva-
lent of 1 ton or more were reported by Belgium, 
Bulgaria,53 Germany, the Netherlands, Romania 
49 E/INCB/2014/4.
50 E/INCB/2015/4.
51 E/INCB/2016/4.
52 Precursors and Chemicals Frequently Used in the Illicit Manu-
facture of Narcotic Drugs and Psychotropic Substances: Report 
of the International Narcotics Control Board for 2011 on the 
Implementation of Article 12 of the United Nations Conven-
tion against Illicit Traffic in Narcotic Drugs and Psychotropic 
Substances of 1988 (E/INCB/2011/4).
53 E/INCB/2016/4.
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reported. Since the start of monitoring by UNODC, 
the number of different NPS reported each year has 
increased year on year, reaching almost 500 differ-
ent substances in 2015. 
Undergoing periods of both innovation and stagna-
tion, the NPS market continues to be very dynamic. 
New substances continue to emerge; some NPS have 
been in the market for years, and others disappear 
over time. Data collection for 2016 is still ongoing, 
but in 2015, 100 NPS were reported globally for 
the first time, a two-thirds increase on the 66 NPS 
reported for the first time in 2014. However, at the 
time of writing, over 70 NPS never previously 
reported were registered by UNODC for 2016, 
which seems to indicate that “innovation” continues 
to be an important element of the NPS market. Yet 
there is a core group of over 80 NPS that show resil-
ience in the global market, having been reported 
every year from 2009 to 2015. This group includes 
several synthetic cannabinoids of the JWH series, 
cannabinoids and synthetic opioids). Data on toxic-
ity, the long-term effects and risk of use remain 
limited for many NPS. 
For the purpose of this report, NPS are defined as 
substances, whether in a pure form or a preparation, 
which are not controlled by the international drug 
control conventions but which may pose a public 
health threat. In that context, the term “new” does 
not necessarily refer to new inventions but to sub-
stances that have recently become available.58 The 
global analysis of NPS includes ketamine, which 
differs from other NPS in that it is widely used in 
human and veterinary medicine, while most NPS 
have little or no history of medical use. A number 
of NPS have been placed under international con-
trol since 2015 and are thus, by definition, no longer 
NPS. However, as this report also covers years when 
they were not yet under international control, and 
the granularity of the data does not always allow a 
separate analysis, they have been included in the 
NPS analysis unless otherwise indicated. When indi-
vidual NPS are discussed, their control status (to 
date) with respect to the international drug control 
conventions is indicated in a footnote. NPS can be 
categorized in terms of similarity in chemical struc-
ture (for example, phenethylamines, tryptamines) 
and/or by their major pharmacological effects (for 
example, cannabinoid receptor agonists). Similarity 
in chemical structure does not always reflect identi-
cal pharmacological effects and a known 
pharmacological effect can be produced by NPS of 
dissimilar chemical structure. For the purpose of 
this report, NPS data are presented in eight catego-
ries. A final category labelled “others” covers 
substances of poorly understood pharmacological 
effects and/or miscellaneous chemical structures.
New psychoactive substances continue 
to spread
The global NPS market continues to be character-
ized by the emergence of large numbers of new 
substances belonging to diverse chemical groups. 
From 2009 and 2016, 106 countries and territories 
reported the emergence of a cumulative total of 739 
different NPS to UNODC. Not all NPS are reported 
every single year, but an increasing number is being 
58 UNODC, The Challenge of New Psychoactive Substances, 
(Vienna, March 2013).
Fig. 8 Number of different new psychoactive 
substances reported each year, 2009-
2015
Source: UNODC, early warning advisory on new psychoactive 
substances. 
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particular, has been associated with rising numbers 
of overdose events among opioid users, including 
fatal intoxications (see chapter B.7, below; and 
booklet 2). 
The proportion of new psychoactive  
substances with stimulant effects is on  
the increase
Notwithstanding the definition of NPS, those sold 
on drug markets may or may not have effects and 
profiles similar to those of the substances under 
international control that they are designed to 
mimic. Analysis of the pharmacological effects of 
NPS reported up to December 2016 revealed that 
the majority of the substances were stimulants, syn-
thetic cannabinoid receptor agonists and classic 
hallucinogens. The number and proportion of NPS 
with stimulant properties has increased in recent 
years, whereas the proportion of synthetic cannabi-
noid receptor agonists, despite growth in numbers 
mephedrone and derivatives, several amphetamine 
analogues and piperazines, as well as a number of 
tryptamines and 2C-B analogues. A number of these 
persistent NPS were placed under international con-
trol in 2015 and 2016, including alpha-PVP, BZP, 
JWH-018, MDPV, mephedrone, methylone and 
PMMA.59 While this persistence at the global level 
does not necessarily indicate widespread use, it sug-
gests that some NPS have a longer “shelf-life” than 
others. On the other hand, about 60 NPS left the 
market after 2013, although it is more challenging 
to determine the group of NPS that have “disap-
peared” as a lack of reports may also be due to 
problems identifying these lesser known substances 
in the laboratory. 
Among all the NPS reported to UNODC by the 
end of 2016, synthetic cannabinoids constitute the 
largest category in terms of the number of different 
substances reported, followed by synthetic cathi-
nones and phenethylamines. Only a comparatively 
small number of tryptamines, piperazines, aminoin-
danes and plant-based NPS are reported annually, 
and those categories constitute only a small propor-
tion of the total number of NPS. The number of 
NPS per category does not necessarily correspond 
to market share or prevalence of use. More evidence 
has become available on the severe adverse health 
consequences associated with the use of NPS, for 
example, synthetic cannabinoids (see chapters B.4 
and B.5, below).
The category of “other substances”, which combines 
structurally diverse substances, has experienced con-
siderable growth since 2013 in terms of the number 
of substances reported. This is mainly down to the 
emergence of NPS-derivatives of prescription medi-
cines, including 18 fentanyl analogues as well as 
derivatives of benzodiazepine and methylpheni-
date.60 The emergence of fentanyl analogues, in 
59 alpha-Pyrrolidinovalerophenone (alpha-PVP) was placed 
under international control in 2016 (Schedule II of the 
1971 Convention). N-benzylpiperazine (BZP), (1-pentyl-
1H-indol-3-yl)-1-naphthalenyl-methanone (JWH-018), 
3,4-methylenedioxypyrovalerone (MDPV), mephedrone 
and methylone were placed under international control  
in 2015 (Schedule II of the 1971 Convention). Para-
methoxymethylamphetamine (PMMA) was placed under 
international control in 2016 (Schedule I of the 1971  
Convention).
60 Methylphenidate was placed under international control in 
1971 (original list, Schedule II of the 1971 Convention).
Fig. 9 Proportion of new psychoactive  
substances, by substance category, 
December 2016
Source: UNODC, early warning advisory on new psychoactive 
substances. Based on the analysis of 739 NPS.
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level, which does not make it possible for data to be 
linked to a specific substance. While in 2010 hardly 
any seizures of synthetic NPS were reported, annual 
amounts have been in the range of 23-54 tons.62 
Seizures of synthetic cannabinoids have dominated 
global seizure amounts since 2011 but recently, the 
amount of synthetic cathinones seized has increased 
considerably. 
While the quantities of synthetic cannabinoids 
reported since 2010 have shown strong year-on-year 
variations, the number of countries reporting sei-
zures of synthetic cannabinoids has shown an 
upward trend, reaching 18 countries in 2015. Sei-
zure data reported to the EU Early Warning System 
in 2014 revealed that of the 50,000 seizures of NPS, 
synthetic cannabinoids comprised the majority of 
cases, with approximately 30,000 seizures amount-
ing to more than 1.3 tons.63 This may be an 
indication that law enforcement is prioritizing syn-
thetic cannabinoids or the fact that those substances 
62 For the purpose of this report, synthetic new psychoactive 
substances exclude plant-based new psychoactive substances 
and ketamine.
63 EMCDDA, European Drug Report: Trends and Developments 
2016.
in absolute terms, has decreased relative to other 
effect groups. Although still small by comparison, 
the largest percentage increase was observed in the 
group of synthetic opioids, which represented 4 per 
cent of all NPS at the end of December 2016 as 
opposed to only 2 per cent at the end of 2014.61
New psychoactive substances seizures and 
manufacture
The analysis of NPS seizures is limited by the fact 
that most substances are not under international 
control and thus may not be seized and reported to 
UNODC as part of the regular data collection 
mechanisms. Often NPS seizures are reported only 
under a product name or at the substance group 
61 UNODC early warning system on new psychoactive  
substances, 2008-2016. 
Fig. 10 Proportion of new psychoactive 
substances, by pharmacological effect, 
December 2016
Source: UNODC, early warning advisory on new psychoactive 
substances. Based on the analysis of 717 NPS. 
Note: The analysis of the pharmacological effects comprises NPS 
registered up to December 2016. Plant-based substances were 
excluded from the analysis as they usually contain a large number 
of different substances some of which may not have been known 
and whose effects and interactions are not fully understood. 
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Fig. 11 Annual amounts of synthetic new 
psychoactive substances seized globally, 
2010-2015
Source: UNODC, responses to annual report questionnaire, 
2010-2015. 
Note: Figures exclude plant-based NPS and ketamine. 
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How widely are new psychoactive  
substances used?
Carried out in 2014, the Eurobarometer survey 
showed 8 per cent lifetime prevalence and 3 per cent 
past-year prevalence of use of NPS among young 
adults (aged 15-24 years) in Europe. Most of the 
respondents who had used NPS in the previous 12 
months obtained them from a friend (68 per cent), 
while about a third bought them from a drug dealer 
(27 per cent).64 Estimates in 2015 among young 
adults aged 15-16 years in the European School 
Survey Project on Alcohol and Other Drugs65 
showed a lower lifetime prevalence of 4 per cent and 
a past-year prevalence of 3 per cent. Information 
from epidemiological surveys on the prevalence of 
use of NPS among the general population is still 
very scarce, one of the few recent examples being 
Germany, where, in 2015, past-year prevalence of 
NPS was at 0.9 per cent among the population aged 
18-64.66 
Trend data on NPS prevalence are still very limited. 
A general problem in understanding NPS use is that 
users often do not know which substance they have 
taken or which substance(s) the product they con-
sume contains. That may partly explain why some 
surveys show an increase while others show stable 
or decreasing trends, at least for specific population 
groups or substances. 
For example, data from a survey of households in 
Ireland and in Northern Ireland showed a decrease 
in the past-year use of NPS. In Ireland and North-
ern Ireland, NPS use among persons aged 15-64 
years dropped significantly between 2010/11 and 
2014/15. Specifically, past-year mephedrone67 use 
was reported to have decreased in Northern Ireland 
from 1.1 per cent in 2010/11 to 0.5 per cent in 
64 European Commission, Young People and Drugs, Flash  
Eurobarometer series No. 401 (August 2014). 
65 EMCDDA and European School Survey Project on Alcohol 
and Other Drugs, ESPAD Report 2015: Results from the 
European School Survey Project on Alcohol and Other Drugs 
(Luxembourg, Publication Office of the European Union, 
2016). 
66 Elena Gomes de Matos and others, “Substanzkonsum in  
der Allgemeinbevölkerung in Deutschland: Ergebnisse des 
Epidemiologischen Suchtsurveys 2015”, SUCHT, vol. 62, 
No. 5 (2016), pp. 271-281.
67 Mephedrone has been under international control as of 
November 2015.
take a larger share of the NPS market than other 
substance groups, or a combination of both. 
B.2. Characteristics of new psycho-
active substances users and trends in 
new psychoactive substances use 
The availability of data on the prevalence of use of 
NPS has improved in recent years but the data are 
still much more limited than data on traditional 
drugs, particularly with respect to trends. Although 
some drug use survey tools have been amended to 
capture NPS use better, the limited knowledge of 
NPS users about the substances they actually use 
continues to pose a challenge, as users may know 
only a brand or street names, which does not neces-
sarily make it possible to identify the substances 
consumed. Thus, NPS use data are often limited to 
specific substances and subpopulations. Another 
key challenge for understanding NPS prevalence of 
use is the varying definitions of which substances 
are considered to be NPS. As that varies from survey 
to survey and may also vary from one respondent 
to another, the notion of NPS used by different 
prevalence surveys may not completely align with 
the group of substances defined as NPS by UNODC. 
Fig. 12 Global quantities seized and number 
of countries and territories reporting 
seizures of synthetic cannabinoids, 
2010-2015 
Source: UNODC, responses to annual report questionnaire,  
2010-2015. 
Note: Contains seizures in the form of herbal material, as well as 
powder and liquids. 
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twelfth-grade students has decreased by more than 
two thirds from 11.4 per cent in 2011 to 3.5 per 
cent in 2016. At the same time, twelfth graders have 
been showing an increased awareness of the dangers 
associated with the use of synthetic cannabinoids. 
Perhaps access to NPS in the United States has been 
reduced by recent legal steps taken to outlaw their 
sale through retail outlets.70
Characteristics and patterns associated 
with new psychoactive substances use 
Some of the characteristics associated with NPS use 
resemble those of traditional drugs, but others are 
specific to NPS. Similar to the recreational use of 
conventional drugs, motivations for NPS use 
reported by users include the search for an experi-
ence involving the paradigm of “modifying 
perceptions”, curiosity, sociability and the search for 
energy or other functional expectations.71 Other 
factors mentioned as driving initial experimentation 
and continued use include boredom and peer social-
ization.72 Features specific to NPS include their 
70 Ibid.
71 Agnès Cadet-Taïrou, “New psychoactive substances: user 
profiles and practices”, Tendances, No. 108 (April 2016).
72 Marie Claire Van Hout and Evelyn Hearne, “A community-
based study of synthetic cannabinoid use in Co. Monaghan, 
Ireland” (July 2015).
2014/15.68 While no clear link has been established, 
government activities aimed at raising awareness 
among drug users about the health risks associated 
with NPS and the introduction of national controls 
took place over the same period. 
The past-year prevalence of use of NPS with 
stimulant effects (reported as “bath salts”) among 
secondary school students in the United States has, 
at 1.3 per cent or less in all grades, remained quite 
low since this category was first included in the 
Monitoring the Future Survey, in 2012. However, 
there has been a statistically significant increase in 
use by eighth graders, from 0.4 per cent in 2015 to 
0.9 per cent in 2016, although annual prevalence 
remains at a low level, with no evidence of a 
progressive increase.69
In recent years, there has been a decrease in the use 
of synthetic cannabinoids among secondary school 
students in the United States: the prevalence of past-
year use of synthetic cannabinoids among 
68 National Advisory Committee on Drugs and Alcohol, 
Prevalence of Drug Use and Gambling in Ireland and Drug 
Use in Northern Ireland, Bulletin No. 1 (Dublin, 2016).
69 Lloyd D. Johnston and others, Monitoring the Future 
National Survey Results on Drug Use, 1975-2015: 2015 
Overview − Key Findings on Adolescent Drug Use (Ann 
Arbor, Michigan, University of Michigan, 2016). 
Fig. 14 Past-year prevalence of cannabis and 
synthetic cannabinoids (“Spice”) use 
among twelfth-grade students, United 
States, 2011-2016
Source: United States National Institute on Drug Abuse, Moni-
toring the Future Survey: National Survey Results on Drug Use  
1975-2016.
0
5
10
15
20
25
30
35
40
20
11
20
12
20
13
20
14
20
15
20
16
Pe
rc
en
ta
ge
 o
f t
w
el
th
-g
ra
de
 st
ud
en
ts
Cannabis
Synthetic cannabinoids
Fig. 13 Past-year prevalence of use of new psycho-
active substances and mephedrone in Ireland 
and Northern Ireland, 2010/11 and 2014/15
Source: National Advisory Committee on Drugs and Alcohol, Preva-
lence of Drug Use and Gambling in Ireland and Drug Use in Northern 
Ireland, Bulletin No. 1 (Dublin, 2016). 
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Recent data collected from wastewater analyses can 
provide deeper insight into local patterns of drug 
use and temporal trends, supplementing existing 
data mechanisms, such as household surveys or other 
epidemiological studies, which do not often cover 
NPS use at the substance level. A study conducted 
in Adelaide, Australia, between 2011 and 2015, 
detected several NPS, namely BZP, TFMPP,79 
mephedrone, methylone, alpha-PVP and MDPV, 
in wastewater samples. The study revealed that 
alpha-PVP, BZP, mephedrone and methylone were 
mostly used at weekends, similarly to the pattern 
reported for cocaine and MDMA. Whereas more 
established drugs such as methamphetamine, 
MDMA or heroin showed relatively regular trends 
in the observation period, NPS trends were charac-
terized by pronounced but short-term peaks in 
particular months. Although the relationship 
between wastewater analysis results and drug use is 
complex, this pattern could indicate that the avail-
ability and/or usage of the NPS investigated was less 
stable than that of established drugs.80 
Although not limited to NPS use, polydrug use 
seems to be one of the features of NPS use. In Eng-
land and Wales, several factors were associated with 
past-year NPS use, including consumption of alco-
hol in the past month and use of another drug in 
the past year.81 Among participants aged 16-59 years 
who had used an NPS in the past year, a total of 
84.9 per cent also reported having used another 
drug.82 In 2015, among European students who 
used NPS, around three quarters used cannabis, 
about a quarter used inhalants and tranquilizers/
sedatives, and less than a quarter used a substance 
in the group of LSD/other hallucinogens and 
“ecstasy”.83 There are insufficient data on NPS as a 
contributing or main factor in the cause of death in 
overdose cases, partly because the pharmacological 
and toxicological properties of many NPS are not 
79 1-(3-Trifluoromethylphenyl)piperazine (TFMPP) is not 
under international control.
80 Benjamin J. Tscharke and others, “Temporal trends in drug 
use in Adelaide, South Australia by wastewater analysis”, 
Science of The Total Environment, vol. 565 (2016), pp. 384-
391.
81 Lader, ed., Drug Misuse: Findings from the 2015/16 Crime 
Survey for England and Wales.
82 Ibid.
83 EMCDDA and European School Survey Project on Alcohol 
and Other Drugs, ESPAD Report 2015.
easier availability, lower price and (assumed) better 
quality compared with traditional drugs. For user 
groups subject to drug screening, such as prisoners, 
their assumed non-detectability in tests is an import-
ant factor. 
Specific social settings have a link to the use of NPS 
in some countries. In England and Wales, for exam-
ple, visits to a bar, pub or a nightclub in the past 
month have been associated with past-year NPS 
use.73 According to the Eurobarometer survey, most 
of the respondents who have used these new sub-
stances in the past 12 months did so at a party or 
event (65 per cent) or with friends (60 per cent), 
although 9 per cent used them during normal daily 
activities.74 Daily use of NPS has also been reported 
in English prisons.75 In New Zealand, in 2015, 
approximately 17 per cent of police detainees, in 
four central city police watch houses, reported 
having used synthetic cannabinoids for the first 
time, the equal highest proportion of all drugs 
reported, as 17 per cent also reported the use of 
methamphetamine.76 
A study in France pointed to a strong link between 
the use of NPS belonging to the phenethylamines 
substance category and the “electro” music scene.77 
Several other factors also played a key role in deter-
mining if NPS were used in a recreational nightlife 
setting. For example, the younger the respondents 
and the lower their education level, the more likely 
NPS use was at the user’s home or a friend’s home 
(private context), and the less likely it was at a party 
or event (public context). There were also variations 
according to the occupational status of the respond-
ents and whether they were the primary household 
earner.78 
73 Deborah Lader, ed., Drug misuse: Findings from the 2015/16 
Crime Survey for England and Wales, 2nd ed., Statistical Bul-
letin 07/16 (London, Home Office, July 2016).
74 European Commission, Young People and Drugs.
75 Rob Ralphs and others, “Adding spice to the porridge: 
the development of a synthetic cannabinoid market in an 
English prison”, International Journal of Drug Policy, vol. 40 
(2016).
76 Chris Wilkins and others, New Zealand Arrestee Drug Use 
Monitoring: 2010-2015 Report (Auckland, SHORE and 
Whariki Research Centre, College of Health, Massey  
University, 2016.
77 Cadet-Taïrou, “New psychoactive substances: user profiles 
and practices”. 
78 European Commission, Young People and Drugs.
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half of them being under 25 years of age, 13 per 
cent being under 20 years of age and 3 per cent of 
respondents being minors,87 although some respond-
ents were over 50 years of age.88, 89  
Gender differences in new psychoactive 
substances use
Gender differences in the prevalence of use of NPS 
vary greatly between countries but may be less pro-
nounced in that of traditional drugs. In Europe, 
gender differences in NPS use in 2015 were small 
at the aggregated regional level but patterns were 
different at the country level. Significantly more 
boys than girls reported the use of NPS at the coun-
try level in Albania, Cyprus, Georgia, Greece, 
Montenegro, the Netherlands and the Republic of 
Moldova, while significantly more girls than boys 
reported the use of NPS in Czechia and Iceland.90 
No significant gender differences in NPS past-year 
prevalence were confirmed in an epidemiological 
survey in Germany among the general population 
in 2015.91 However, in the Crime Survey for Eng-
land and Wales in 2015/16, of the general 
population, men (1.1 per cent) were, statistically, 
significantly more likely to have used an NPS in the 
past year than had women (0.4 per cent), and a 
similar gender difference was found among partici-
pants aged 16-24 years.92 
New psychoactive substances and  
traditional drug markets
The initial expansion of the NPS market may have 
happened at the expense of use of traditional drugs 
because of the comparative advantage of NPS in 
terms of low prices and quasi legal status, yet more 
recent studies are providing evidence that some NPS 
have now established a market in their own right. 
87 I-TREND (Internet tools for research in Europe for new 
drugs) project, which was co-funded by the European  
Commission.
88 Cadet-Taïrou “New psychoactive substances: user profiles 
and practices”.
89 American Association of Poison Control Centers, Alerts, 
Synthetic cannabinoids. Available at www.aapcc.org/alerts/
synthetic-cannabinoids/.
90 ESPAD Report 2015.
91 Gomes de Matos and others, “Substanzkonsum in der 
Allgemeinbevölkerung in Deutschland”.
92 Lader, ed,. Drug misuse: Findings from the 2015/16 Crime 
Survey for England and Wales.
yet fully understood, and overdose cases often 
involve polydrug use.
New psychoactive substances use among 
vulnerable and high-risk groups
Some studies have shown that selected groups, such 
as young people, people in contact with mental 
health services, people affected by homelessness, 
people who inject drugs (PWID) and men who have 
sex with men (MSM), are particularly vulnerable to 
NPS. In a survey among such vulnerable groups in 
Scotland, 59 per cent of respondents reported having 
used an NPS, most of them in the past six months. 
The most commonly used NPS were synthetic can-
nabinoids (41 per cent), followed by NPS with 
stimulant effects (21 per cent) and mephedrone (19 
per cent).84  As some NPS are more affordable than 
traditional drugs with similar effects, the homeless 
and marginalized people in general are more prone 
to NPS use. For example, alpha-PVP is sold in the 
United States in quantities as small as one tenth of 
a gram, for as little as $3-5, a price affordable among 
population groups with little disposable income, 
including young or socially disadvantaged people. 
There are also reports of these substances being 
actively sold to, and by, homeless persons.85, 86
As traditional drugs, NPS have a higher use among 
youth. Surveys in European countries indicate that 
NPS use is often concentrated among those around 
20 years of age. The Crime Survey for England and 
Wales for the reporting year 2015/16 estimated that 
0.7 per cent of adults aged 16 to 59 years (around 
244,000 people) had used an NPS in the past year, 
with prevalence of use highest among young adults 
aged 16 to 24 years, at 2.6 per cent. A survey of 
NPS users conducted in 2014 in Czechia, France, 
the Netherlands and Poland also showed that the 
majority of users were young adults, with almost 
84 Katy MacLeod and others, Understanding the Patterns of 
Use, Motives, and Harms of New Psychoactive Substances in 
Scotland, Social Research Series (Edinburgh, November 
2016). Mephedrone was not included into the new psycho-
active substances category in this study.
85 National Drug Early Warning System (NDEWS) Coordi-
nating Center, Southeastern Florida (Maimi Area), Sentinel 
Community Site, Drug Use Patterns and Trends (2016).  
Available at http://miamicoalition.org/doc/florida_scs_
drug_use_patterns_and_trends_2016.pdf.
86 MacLeod and others, Understanding the Patterns of Use, 
Motives, and Harms of New Psychoactive Substances in  
Scotland.
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Studies showing a replacement effect for NPS 
include a wastewater analysis in South Australia, in 
which the average weekly use of certain NPS (i.e., 
BZP, mephedrone, MDPV, and TFMPP) increased 
when MDMA became less available in 2010 to 
2011, while the use of those NPS decreased once 
MDMA became available again. The study sug-
gested that changes in the use of those NPS might 
be driven by irregular supply rather than by changes 
in demand.93 Meanwhile, in a community study in 
Ireland, easy availability of NPS also appeared first 
and foremost as driver for introduction and use.94
In prisons in the United Kingdom and the United 
States, synthetic cannabinoids seem to be used as a 
replacement for cannabis, possibly because they may 
remain undetected in mandatory drug screens.95, 96 
Moreover, synthetic cannabinoids were reported to 
be used among United States military personnel, 
probably to evade detection, as current workplace 
drug tests can only detect some but not all synthetic 
cannabinoids in use.97 Similarly, in Scotland, some 
youth offenders and individuals in treatment pro-
grammes have switched to mephedrone in the belief 
that it will not be picked up by tests to detect drug 
use.98 In France, in a drug user survey, the main 
reason reported for choosing the last substance that 
the respondent used was “curiosity” (50 per cent), 
while the perceived danger to health of a substance, 
the control status and its perceived non-detectability 
in urine or saliva drug tests were criteria that seem 
to have played a secondary role in the choice of 
substance.99
93 Tscharke and others, “Temporal trends in drug use in Ade-
laide, South Australia by wastewater analysis”. In this study, 
use was expressed as average weekly use (doses/week/1,000 
people or mg excreted/week/1,000 people).
94 Van Hout and Hearne, “A community-based study of  
synthetic cannabinoid use in Co. Monaghan, Ireland”.
95 Nicola J. Kalk and others, “Spice and all things nasty:  
the challenge of synthetic cannabinoids”, British Medical 
Journal, vol. 355 (2016).
96 E. D. Wish, A. S. Billing and E. E. Artigiani, Community 
Drug Early Warning System: The CDEWS‐2 Replication Study 
(Washington, D. C., Office of National Drug Control 
Policy, Executive Office of the President, 2015). 
97 United States, Drug Enforcement Administration, 2016 
National Drug Threat Assessment Summary. 
98 Alex Chadd, “Mephedrone emergence in southern Wales” 
(2013), presentation. 
99 Cadet-Taïrou, “New psychoactive substances: user profiles 
and practices”.
The fact that NPS have now become drugs of choice 
for certain user groups or in certain settings is vis-
ible in other studies, including the Global Drug 
Survey, although the comparability of different years 
is limited and the change in motivational factors for 
the use of NPS should be interpreted with caution. 
While the primary reason for NPS use reported four 
years ago was the non-availability and the poor qual-
ity of traditional drugs, in 2015 and 2016, NPS 
were reportedly used instead for their perceived value 
for money and ease of access, specifically via online 
services.100 In another study in Scotland, only a very 
small number of study participants (3-6 per cent) 
who had used NPS equivalents to “traditional’’ drugs 
in the past 6 months did so because they thought 
they would be safer.101 
B.3. How well-informed are users of 
new psychoactive substances and 
how concerned are they about what 
they are using? 
The purity and composition of products containing 
NPS are often unknown, and safety data on the 
toxicity of many NPS, as well as information on the 
long-term adverse effects and risks, are unavailable 
or are very limited, which places users at high risk. 
The great lack of awareness and knowledge about 
the risks and harms related to dosages and the use 
of NPS is demonstrated by studies among men who 
have sex with men (MSM), night clubbers, prison-
ers, and by poison centre records. Younger, 
potentially new users seem to be less aware and 
informed about the drugs they take, while experi-
enced drug users appear to be more aware and 
careful about the composition, effects and dosages 
of drugs they take. 
In a survey of MSM in Scotland, 54 per cent 
reported lifetime use of NPS and almost a quarter 
of synthetic cannabinoid users reported first using 
synthetic cannabinoids without knowing that they 
were taking a substance from that group.102 A study 
conducted to assess NPS and drug use among 679 
nightclub/festival-attending young adults (aged 
100 Global Drug Survey 2016 findings. Available at www.
globaldrugsurvey.com.
101 MacLeod and others, Understanding the Patterns of Use, 
Motives, and Harms of New Psychoactive Substances in  
Scotland.
102 Ibid.
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According to the Global Drug Survey 2017, the 
overall risk of seeking emergency medical treatment 
was highest for the use of synthetic cannabinoids 
among NPS.108 One likely reason is that different 
substances are sprayed in varying proportions and 
dosages on the herbal material of NPS products of 
the same brand, which increases the risk of adverse 
health consequences for users.109 
A study in Ireland on the profile of NPS users 
investigated the risk awareness and dependence 
potential of synthetic cannabinoids. The study 
interviewed only dependent user participants who 
described their intention to stop using the 
substances, although unpleasant physical and mental 
withdrawal symptoms prevented them from doing 
so. The fear of stopping use was also grounded in 
youth psychotic behaviours, suicidal ideation and 
suicide attempts when in withdrawal. However, user 
108 The definition of NPS used in the Global Drug Survey is 
not comparable to the definition used by the UNODC.
109 Global Drug Survey 2017, detailed findings on drug  
cryptomarkets. Available from Dr. Monica Barratt,  
National Drug and Alcohol Research Centre, Australia.
18-25 years) in New York City revealed that of those 
respondents who reported no lifetime use of stimu-
lant NPS, unknown pills or powders, 41.2 per cent 
tested positive for NPS with stimulant effect. Results 
suggest that many “ecstasy”-using nightclub/festival 
attendees may be unintentionally using “bath salts” 
or other products containing NPS.103
Callers to poison centres in the United Kingdom 
reported the specific chemical involved in branded 
products in only 8 of the 108 telephone enquiries 
(7.4 per cent) relating to synthetic cannabinoids.104 
In France, about 64 per cent of users indicated that 
they did not have enough information on the NPS 
they were using. However, more than two thirds of 
NPS users reported the purchase of NPS mainly 
from websites where they are sold under their chemi-
cal names, rather than from websites that display 
brand names and colourful packaging, without 
giving specific chemical information.105 
Risk perception and harms reported by 
new psychoactive substances users
There is a severe lack of information on the risks of 
NPS use, particularly when (unknown) combina-
tions of substances are consumed. For example, 
prisoners who use NPS stated that they had no idea 
what “Spice” contained and what it might do to 
their bodies, and that they only had personal and 
others’ experiences to draw upon, suggesting that 
potential physical harm does not deter prisoners 
from continued use.106 As reported by the Euroba-
rometer survey, however, a large majority of all 
respondents considered regular use of NPS to carry 
a high risk to health, although they believed that 
using these new substances only once or twice car-
ries less risk.107 
103 Joseph J. Palamar and others, “Detection of “bath salts” 
and other novel psychoactive substances in hair samples of 
ecstasy/MDMA/”Molly” users, Drug and Alcohol Depend-
ence, vol. 161 (2016), pp. 200-205.
104 United Kingdom, Public Health England, National Poisons 
Information Service Report 2015/2016 (September 2016).
105 Cadet-Taïrou, “New psychoactive substances: user profiles 
and practices”.
106 User Voice, “Spice: the bird killer — what prisoners think 
about the use of spice and other legal highs in prison” (May, 
2016).
107 European Commission, Young People and Drugs. 
Fig. 15 Extent of perceived risk to a person’s 
health posed by the use of new psy-
choactive substances, Europe, 2014
Source: European Commission, Young People and Drugs, Flash 
Eurobarometer series No. 401, (August 2014). 
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rate than other PWID and are more likely to share 
needles and other contaminated injecting parapher-
nalia.113 Users at risk include young people, 
subgroups of MSM, long-term abstinent former 
opiate users, people who inject other drugs such as 
heroin and amphetamines, people who switch to 
injecting synthetic cathinones and people who have 
switched from snorting to injecting. This points to 
the growing interplay between NPS and traditional 
illicit drug markets, with specifically synthetic cathi-
nones, e.g., mephedrone, MDPV and pentedrone 
being used by PWID.114 
In an analysis conducted in Paris in 2012 on the 
residual content of 3,489 used syringes collected 
from 17 automatic injection kit dispensers, opiate 
substitutes and new compounds including the syn-
thetic cathinone 4-MEC115 were found at all sites. 
Heroin was detected in 42 per cent of cases, followed 
by cocaine in 41 per cent of cases, buprenorphine 
in 29 per cent of cases, and 4-MEC in 23 per cent 
of cases. Over the course of 2012, 4-MEC was 
detected in an increasing number of syringes 
between the summer and the winter months, point-
ing to an increase in the use of the substance at a 
time when cocaine consumption decreased.
National data on PWID attending syringe exchange 
programmes in Hungary from 2011 to 2015 has 
shown a transition from injecting use of ampheta-
mine and heroin to NPS. Over a five-year period, 
there was a significant decrease in the percentage of 
PWID reporting amphetamine as the primary 
injected drug, as well as heroin and an increase in 
injecting use of NPS, which more than tripled in 
the same period.116
113 Andrea Fischer and others, The Link between Amphetamine-
Type Stimulant Use and the Transmission of HIV and other 
Blood-borne Viruses in the Southeast Asia Region, ANCD 
Research Paper No. 25 (Melbourne, National Drug 
Research Institute, Australian National Council on Drugs, 
2013).
114 Mephedrone and MDPV were placed under international 
control, in Schedule II of the 1971 Convention in 2015. In 
March 2017, the Commission on Narcotic Drugs decided 
to add pentedrone to the same Schedule. 
115 In March 2017, the Commission on Narcotic Drugs 
decided to place 4-methylethcathinone (4-MEC) under 
international control (Schedule II of the 1971 Convention).
116 Anna Tarján and others, “HCV prevalence and risk behav-
iours among injectors of new psychoactive substances 
in a risk environment in Hungary: an expanding public 
health burden”, International Journal of Drug Policy, vol. 41 
awareness about the dangers of smoking synthetic 
cannabinoid products was low.110 
Concerning the harms associated with NPS use, 
respondents to a survey in Scotland in 2016 who 
had used an NPS in the previous six months reported 
anxiety, paranoia and depression. Moreover, the 
majority of respondents reported negative effects on 
their family relationships relating to NPS use. The 
key reasons for stopping the use of NPS were related 
to “not liking it” or to specific harms that individu-
als had experienced, such as a negative impact on 
mental or physical health.111 
B.4. Health risks of new psychoactive 
substances with stimulant effects
NPS can be grouped into six pharmacological effect 
groups, one of them being NPS with stimulant 
effects. This group consists of structurally diverse 
substances including aminoindanes, synthetic cathi-
nones, piperazines and phenethylamines, which act 
as stimulants of the central nervous system by medi-
ating the actions of dopamine, norepinephrine and 
serotonin. Accounting for 36 per cent of all sub-
stances reported to UNODC up to December 2016, 
NPS with stimulant effects have a mechanism of 
action similar to traditional drugs such as cocaine, 
amphetamine, methamphetamine and “ecstasy”. 
The reported health risks and harm associated with 
the use of NPS with stimulant effects, particularly 
their injecting use, gives great cause for concern as 
it has been associated with increasing rates of HIV 
infection. 
High-risk groups injecting new psycho-
active substances with stimulant effects
The injecting use of NPS with stimulant effects has 
been reported among high-risk drug user groups, 
further aggravating the health risks that persons in 
this group are particularly exposed to.112 The inject-
ing use of stimulants increases the health risks of 
users as they are prone to inject at a more frequent 
110 Van Hout and Hearne, “A community-based study of  
synthetic cannabinoid use in Co. Monaghan, Ireland”.
111 MacLeod and others, Understanding the Patterns of Use, 
Motives, and Harms of New Psychoactive Substances in  
Scotland.
112 High-risk drug users are defined as people who inject drugs, 
people who use drugs on a daily basis and/or people diag-
nosed as drug-dependent.
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frequently detected cathinone derivative at 26 per 
cent. However, in the majority of cases of the analy-
sis of the residual content of injecting equipment 
in 2015, the identity of the active substance was not 
confirmed.121
In the United Kingdom, there have also been reports 
of injecting use of mephedrone, methamphetamine 
and GHB immediately before or during sex in 
groups of MSM in the past year. Commonly referred 
to as “slamming”, careful injecting use with clean 
needles was reported, with no sharing of needles 
between sexual partners at “chemsex” parties122 
(more information on GHB can be found in chapter 
B.7, below). There are also concerns about the injec-
tion of mephedrone and other drugs among some 
subgroups of MSM during sex, who often share 
injecting equipment and engage in unprotected 
sex.123
international control. 
121 EMCDDA, 2015 National Report to the EMCDDA by the 
Reitox National Focal Point: Hungary.
122 Adam Bourne and others, ““Chemsex” and harm reduction 
need among gay men in South London”, International Jour-
nal of Drug Policy, vol. 26, No. 12 (2015), pp. 1171-1176.
123 Adam Bourne and others, The Chemsex Study: Drug Use 
in Sexual Settings Among Gay and Bisexual Men in Lam-
beth, Southwark and Lewisham (London, Sigma Research, 
London School of Hygiene and Tropical Medicine, 2014); 
Victoria L. Gilbart and others, “High-risk drug practices 
in men who have sex with men”, The Lancet, vol. 381, 
No. 9875 (2013), pp. 1358 and1359; and David Stuart, 
“Sexualised drug use by MSM: background, current status and 
By mid-2010, needle and syringe programmes in 
Hungary reported a sharp increase in the injecting 
use of mephedrone, with participants reportedly 
seeking the euphoric effects in the early stages after 
injection. The stimulating effect of mephedrone 
enabled previous heroin users to take part in collec-
tive use, rather than earlier individual use, and that 
factor played an important role in the quick spread 
of mephedrone use.117 In 2011, MDPV became 
the main substance injected by PWID, with inject-
ing use of mephedrone and 4-MEC reported at a 
lower rate. By 2012, the synthetic cathinone pent-
edrone had become the predominant substance 
injected by PWID, accounting for about 43 per cent 
of active substances detected in the residual contents 
of injecting equipment, a trend that continued until 
2013.118 In 2014, alpha-PVP was the most detected 
substance in the residual contents of syringes, at 40 
per cent, while pentedrone had decreased to 9.5 per 
cent.119 In 2015, alpha-PHP120 became the most 
(2017), pp. 1-7.
117  József Rácz, Róbert Csák and Sándor Lisznyai, “Transi-
tion from “old” injected drugs to mephedrone in an urban 
micro segregate in Budapest, Hungary: a qualitative analysis”, 
Journal of Substance Use, vol. 20. No. 3 (2015), pp. 178-186.
118 Anna Péterfi and others,”Changes in patterns of injecting 
drug use in Hungary: a shift to synthetic cathinones”, Drug 
Testing and Analysis, vol. 6, Nos.7 and 8 (2014), pp. 825-
831.
119 EMCDDA, 2015 National Report to the EMCDDA by the 
Reitox National Focal Point: Hungary (Budapest, 2015).
120 Alpha-pyrrolidinohexanophenone (alpha-PHP) is not under 
Fig. 16 Breakdown of clients of syringe exchange programmes, by primary injected drug, Hungary, 
2011-2015 
Source: Hungary, syringe distribution and client data from national syringe exchange programmes, 2011-2015.
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Increase in HIV and hepatitis C infections 
associated with injecting stimulant new 
psychoactive substances
Synthetic cathinones, alone or in combination with 
other stimulants (e.g., methamphetamine and 
cocaine) are injected to enhance sexual experiences, 
and users report compulsive re-injecting because of 
the substances’ relatively short duration of action. 
Thus, people who inject synthetic cathinones may 
be at a higher risk of acquiring and transmitting 
HIV than NPS users who do not inject and people 
who inject other drugs. Risky sexual behaviour such 
as unprotected sex, to which the stimulant and 
euphoric effects of such substances may contribute, 
can also be an important factor in acquiring or trans-
mitting HIV, as well as hepatitis C to some extent.
A study conducted in 2012 and 2013 on the 
epidemiology of synthetic drug use among a cohort 
of PWID in San Diego, California, showed that a 
considerable proportion of PWID use synthetic 
drugs and experience harms associated with their 
use. Of the 485 respondents, 31 PWID (7 per cent) 
reported lifetime use of synthetic cathinones such 
as mephedrone, MDPV and methylone. Injecting 
was reported as the most common route of 
administration (48 per cent) among PWID, followed 
by snorting (36 per cent) and smoking (23 per cent). 
Compared with PWID who did not report synthetic 
cathinone use, people who inject synthetic 
cathinones were more likely to have initiated 
injecting drug use with stimulants and less likely to 
have initiated injecting drug use with heroin, were 
significantly younger (34 years old on average versus 
45 years old) and were more likely to be HIV-
positive. Moreover, rates for receptive syringe 
sharing, hospitalization and the use of other drugs 
in the previous six months were higher for those 
who injected synthetic cathinones than for those 
who did not.124 
In Romania, data from a needle and syringe pro-
gramme in Bucharest showed that HIV infections 
through injecting drug use have increased since 2009 
and that the primary type of drug injected among 
response”, HIV Nursing, vol. 13, No. 1 (2013), pp. 6-10.
124 Karla D. Wagner and others, “Use of synthetic cathinones 
and cannabimimetics among injection drug users in San 
Diego, California” Drug and Alcohol Dependence, vol. 141 
(2014), pp. 99-106.
PWID has become NPS (97 per cent) in place of 
heroin.125 This might suggest that NPS injecting is 
related to a higher rate of HIV-positive cases among 
injecting drug users. 
In Ireland, an unexpected increase in the number 
of acute HIV infection cases among PWID might 
be linked to an increase in injecting use of the syn-
thetic cathinone, alpha-PVP, among the homeless 
population.126 Injecting was reported to occur mul-
tiple times a day, with users often reusing syringes 
and sharing filters. All users that reported injecting 
methamphetamine also reported injecting 
alpha-PVP.
Public Health England pointed to an increase in the 
125 European Centre for Disease Prevention and Control/
WHO Regional Office for Europe, HIV/AIDS Surveillance 
in Europe, 2015 (Stockholm, 2016).
126 C. Giese and others, “Injection of new psychoactive sub-
stance snow blow associated with recently acquired HIV 
infections among homeless people who inject drugs in 
Dublin, Ireland, 2015”, Eurosurveillance, vol. 20, No. 40 
(2015), pp. 1-6.
Fig. 17 HIV prevalence among people who inject  
drugs and primary drugs used among par-
ticipants in needle and syringe programmes, 
Romania, 2005-2013 
Source: Romania, National Anti-drug Agency. 
The prevalence of HIV refers to tested PWID in treatment services.
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equipment (past month), roughly doubled from 
2011 to 2014, significantly exceeding prevalence in 
other PWID groups. Among young adults up to 25 
years of age, prevalence of hepatitis C infection 
increased about sixfold. At the same time, the esti-
mated number of syringes distributed per PWID 
nationally fell from 114 in 2011 to 28 in 2015.131 
A slight increase in the injecting use of synthetic 
cathinones was reported by needle and syringe pro-
gramme clients in 2015.
Other adverse health events of stimulant 
new psychoactive substances use
In early 2014, Scotland experienced a large outbreak 
of soft-tissue infections among people who inject 
drugs132 during the period when the injecting of 
ethylphenidate, mainly by previous injecting users 
of heroin, suddenly increased. The use of this 
relatively short-acting stimulant is known to increase 
injection frequency and thus the associated risks.133 
Consequently, ethylphenidate, which had significant 
adverse effects on physical and mental health, 
including hospitalization and death,134 was placed 
under temporary control in the United Kingdom 
in April 2015.135 Based on the analysis of needle 
exchange data from the NHS, people that reported 
current injecting use of NPS (exclusively stimulant 
NPS) indicated that the average frequency of 
injecting was five times per day. In addition, they 
reported incidences of equipment sharing and poor 
injecting technique, which can lead to health 
complications.136
131 Tarján and others, “HCV prevalence and risk behaviours 
among injectors of new psychoactive substances in a risk 
environment in Hungary”.
132 Health Protection Scotland, HPS eWeekly Report, “Out-
break of soft tissue infections: injected ‘legal highs’”, 31 
March 2015. Available at www.hps.scot.nhs.uk/documents/
ewr/pdf2015/1513.pdf.
133 Con Lafferty and others, “The experience of an increase 
in the injection of ethylphenidate in Lothian April 2014-
March 2015”, Scottish Medical Journal, vol. 61, No. 2 
(2016).
134 “Ethylphenidate (EPH): critical review report” (report of 
the World Health Organization Expert Committee on Drug 
Dependence, Thirty-eighth Meeting, 14-18 November 
2016).
135 In March 2017, the Commission on Narcotic Drugs 
decided to place ethylphenidate under international control 
(Schedule II of the 1971 Convention). 
136 MacLeod and others, Understanding the Patterns of Use, 
Motives, and Harms of New Psychoactive Substances in  
Scotland.
number of people injecting stimulants, with concern 
being expressed about the fact that within five years 
of the first appearance of mephedrone, around 1 in 
10 PWID reported its injecting use. Among the 
population surveyed in England, Wales and North-
ern Ireland, injecting use of mephedrone during the 
preceding month was reported by 5.9 per cent (92 
out of 1,554) of PWID in 2014. Mephedrone inject-
ing occurred mainly among people who had 
previously injected other drugs, people who had 
switched from snorting mephedrone and among 
younger people. Those who reported that they had 
injected mephedrone during the preceding year were 
more likely to have reported HIV infection, anti-
bodies to the hepatitis C virus and injection site 
infections.127 
Lack of knowledge of the substance regarding purity, 
dosing, effects and health consequences, as well more 
frequent injecting practices, increases the risks 
related to synthetic cathinone use. The health harms 
associated with injecting use of pentedrone were 
shown in a study on HIV among PWID in Hun-
gary. Some 92 out of 167 PWID tested positive for 
HIV, with the most common drug injected being 
pentedrone.128 Furthermore, hepatitis C infection 
was reported to be more prevalent among people 
who inject NPS with stimulant effects, since the 
short duration of action from injecting use of some 
synthetic drugs leads to a high-frequency use pat-
tern.129 The prevalence of hepatitis C infection 
among PWID in Budapest increased from 41 per 
cent in 2013 to 60 per cent in 2014, indicating that 
factors favouring the spread of injecting related 
infections were present among PWID.130 Among 
persons injecting NPS, prevalence of hepatitis C 
infection, sharing syringes and sharing any injecting 
127 United Kingdom, Public Health England, Health Protec-
tion Scotland, Public Health Wales, and Public. Health 
Agency Northern Ireland, “Shooting up: infections among 
people who inject drugs in the United Kingdom” (London, 
November 2015).
128 József Rácz, V. Anna Gyarmathy and Róbert Csák, “New 
cases of HIV among people who inject drugs in Hungary: 
false alarm or early warning?, International Journal of Drug 
Policy, vol. 27 (2016), pp. 13-16.
129 “Injecting of new psychoactive substances and related risks 
in Hungary.” PDU annual expert meeting, EMCDDA, 
Lisbon, 27 September 2013. Gergely Horvath, Hungarian 
national focal point.
130 József Rácz, V. Anna Gyarmathy and Róbert Csák, “New 
cases of HIV among people who inject drugs in Hungary: 
false alarm or early warning?”. 
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Typically, one or several synthetic cannabinoids are 
soaked in or sprayed onto plant material, which itself 
does not contain substances with psychoactive effects. 
Synthetic cannabinoids are also sold in liquid form 
and, more recently, have been presented in the 
United States in the form of pills, as counterfeit pre-
scription drugs.142 Products containing synthetic 
cannabinoids are often highly variable both in the 
quantity of active ingredients and number of differ-
ent synthetic cannabinoids present, and thus pose a 
public health risk.
Between 2008 and 2016, over 240 different syn-
thetic cannabinoids were reported to UNODC by 
65 Member States, with year-on-year figures show-
ing significant increases in substances reported, up 
to 2014, while the figures for 2015 showed a slight 
decrease from 2014. Although not all the substances 
identified to date have been present every single 
year, the number of different synthetic cannabinoids 
constitutes a challenge for forensic laboratories and 
emergency services.143 
Evolution of synthetic cannabinoids 
Since the discovery of the cannabinoid receptors in 
the 1980s and the ensuing research for potential 
therapeutic agents,144 the development of synthetic 
cannabinoids has experienced continued growth, 
with the evolution of a series of different structural 
classes. Products containing synthetic cannabinoids 
first appeared in the mid-2000s, which were sold as 
smokable “herbal blends” and “legal highs” under 
a variety of brand names such as “Spice”, “K2”, 
“Kronic” and labelled “not for human consumption”. 
A post-2008 phenomenon occurred as successive 
structural modifications were introduced to keep 
synthetic cannabinoids in an ambiguous legal 
status.145 For instance, the emergence of the first 
wave of naphthoylindoles (for example, JWH-018) 
developed into naphthoylindazoles such as THJ-
018, indazole carboxamides such as AKB-48, and 
142 2016 National Drug Threat Assessment Summary.
143 UNODC early warning advisory on new psychoactive  
substances, 2016.
144 Leslie Iversen, “Cannabis and the brain”, Brain, vol. 126, 
No. 6 (2003), pp. 1252-1270.
145 Ruri Kikura‐Hanajiri and others, “Changes in the preva-
lence of new psychoactive substances before and after the 
introduction of the generic scheduling of synthetic can-
nabinoids in Japan”, Drug Testing and Analysis, vol. 6, Nos. 
7 and 8 (2014), pp. 832-839.
In the United States, increased reports of alpha-PVP, 
allegedly used as an alternative to cocaine, were 
observed from 2011 to 2015. Among impaired driv-
ers tested in the State of Maine, 6 per cent of 
urinalyses tested positive for alpha-PVP and MDPV 
in 2012; the proportion decreased to 2 per cent in 
2013. In 2012, two deaths were caused by alpha-
PVP.137 In Florida, an outbreak of alpha-PVP use 
was observed, which led to the substance being 
linked to 80 deaths and thousands of hospital emer-
gency cases, many from excited delirium syndrome, 
from September 2014 to December 2015.138 
Excited delirium involves hyperstimulation, para-
noia and hallucinations that can lead to violent 
aggression and self-injury. In 2015, alpha-PVP was 
linked to 63 deaths and more than 1,800 hospital 
emergency cases in one county alone in south-east 
Florida.139 
B.5. Synthetic cannabinoids: toxicity 
and fatalities 
Synthetic cannabinoid receptor agonists, also known 
as synthetic cannabinoids, are man-made substances 
designed to mimic the desired effects of cannabis. 
Their potency may, however, vary significantly from 
that of cannabis, although extremely potent syn-
thetic cannabinoid receptor agonists produce effects, 
such as agitation, that are similar to intoxication by 
the major psychoactive component of cannabis, del-
ta-9-tetrahydrocannabinol (THC), a partial 
agonist140 of the cannabinoid receptors. Synthetic 
cannabinoid receptor agonists constitute the largest 
NPS group in the drug market in terms of the 
number of different substances reported. Many of 
the substances in this structurally diverse group were 
initially designed for pharmacological research and 
none are currently licensed for medical use.141 
137 Marcella H. Sorg, “Drug abuse patterns and trends in 
Maine”, update: January 2014. Available at www.drugabuse.
gov. 
138 “Southeastern Florida (Miami Area), Sentinel community 
site, drug use patterns and trends (2016)”, NDEWS  
Coordinating Center.
139 Ibid.
140 An agonist is a substance that acts on a receptor to pro-
duce effects. A partial agonist is a substance that produces 
a reduced response as it is unable to elicit the maximum 
effect or response. For more information, see Terminology 
and Information on Drugs (United Nations publication, 
Sales No. E.16.XI.8).
141 Terminology and Information on Drugs (United Nations 
publication, Sales No. E.16.XI.8).
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overall effects of cannabis, including its anxiolytic 
properties. Synthetic cannabinoids pose a consider-
able risk to public health for a number of reasons, 
and many of those that appear in different products 
can be much more potent than THC.147 
Public health harms and risks associated 
with the use of synthetic cannabinoids
Synthetic cannabinoids have structural features that 
allow binding to the cannabinoid receptors within 
the body. Many synthetic cannabinoids, such as 
JWH-018 and AM-2201,148 are more potent than 
THC149, 150 and are associated with increased severe 
adverse events and greater toxicity.151 A number of 
toxic effects have been reported by users of synthetic 
cannabinoids, including seizures, loss of conscious-
ness, psychosis, vomiting, drowsiness, chest pain, 
agitation, hot flushes, dilation of pupils and a dry 
mouth. Evidence also suggests that tolerance or 
withdrawal symptoms may occur when use is dis-
continued following regular chronic use.152
147 Terminology and Information on Drugs (United Nations 
publication, Sales No. E.16.XI.8).
148 AM-2201 [1-(5-fluoropentyl)-1H-indol-3-yl]-1-naphtha-
lenylmethanone has been under international control since 
2015 (Schedule II of the 1971 Convention). 
149 G S. M. R. Gurney and others, “Pharmacology, toxicology, 
and adverse effects of synthetic cannabinoid drugs”, Forensic 
Science Review, vol. 26, No. 1 (2014), pp. 53-78.
150 Ziva D. Cooper, “Adverse effects of synthetic cannabinoids: 
management of acute toxicity and withdrawal”, Current 
Psychiatry Reports, vol. 18, No. 5 (2016).
151 Robert Kronstrand and others, “Toxicological findings of 
synthetic cannabinoids in recreational users”, Journal of 
Analytical Toxicology, vol. 37, No. 8 (2013), pp. 534-541.
152 “Critical review of psychoactive substances: JWH-018 and 
AM-2201 in WHO Expert Committee on Drug Dependence: 
Thirty-sixth Report, WHO Technical Report Series, No. 991 
(Geneva, World Health Organization, 2014).
indole carboxamides such as MDMB-CHMICA, 
which have emerged more recently.146 New 
derivatives of synthetic cannabinoids that have 
emerged in the drug market have generated more 
potent and dangerous substances with detrimental 
effects on humans.
Composition of cannabis and synthetic 
cannabinoids
Synthetic cannabinoids are not simply synthetic 
versions of the substances occurring in herbal can-
nabis, as street names such as “synthetic cannabis” 
and “synthetic marijuana” might suggest. Rather, 
based on the reported differences in potency, toxic-
ity, duration of effects and pharmacology, synthetic 
cannabinoids could be described as a group of sub-
stances with both similarities to cannabis, such as 
acting on the same receptors, and significant differ-
ences, such as lacking the effects of other components 
of herbal cannabis, including cannabidiol (CBD). 
Although not psychoactive, CBD contributes to the 
146 THJ-018 (1-naphthalenyl-(1-pentyl-1H-indazol-3-yl)-meth-
anone) and 5F-AKB-48 (also known as 5F-APINACA or 
N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-car-
boxamide) are not under international control. In March 
2017, the Commission on Narcotic Drugs decided to 
place MDMB-CHMICA (methyl 2-(1-(cyclohexylmethyl)-
1H-indole-3-carboxamido)-3,3-dimethylbutanoate) under 
international control (Schedule II of the 1971 Convention). 
Fig. 19 Examples of chemical modifications 
leading to new synthetic cannabinoids 
(A) The naphthoylindole, JWH-018, (B) The naphthoylindazole THJ-
018, (C) the indazole carboxamide AKB-48, also known as “APIN-
ACA”, and the indole carboxamide (D) MDMB-CHMICA. The areas 
of the structures marked in red show the chemical modifications. 
Fig. 18 Number of synthetic cannabinoids 
reported yearly to the UNODC early 
warning advisory from 2009 to 2015 
Source: UNODC early warning advisory on new psychoactive 
substances. 
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In Poland, a large outbreak of several hundred intox-
ications was registered in 2015, including at least 
three fatal cases, caused by the use of an NPS prod-
uct known as “Mocarz” (Strongman), which 
contained a mixture of synthetic cannabinoids.159 
The presence of MDMB-CHMICA was recorded 
and reports suggested that even low doses of the 
substance could have fatal consequences. More 
intoxications and fatal cases associated with the use 
of synthetic cannabinoids may have remained unde-
tected because of knowledge gaps in toxicology, 
particularly of newly emerging substances, and the 
interaction between synthetic cannabinoids and 
other drugs.160 
Violence in prisons associated with  
synthetic cannabinoid use
The use of synthetic cannabinoids in prisons is 
becoming an increasingly pronounced issue in the 
United Kingdom, where reports associate prison 
violence and adverse health effects with the use of 
159 Piotr Adamowicz, “Fatal intoxication with synthetic  
cannabinoid MDMB-CHMICA”, Forensic Science Inter-
national, vol. 261 (2016), pp. e5-e10.
160 Laura M. Labay and others, “Synthetic cannabinoid drug 
use as a cause or contributory cause of death”, Forensic  
Science International, vol. 260 (2016), pp.31-39.
The high potency and associated toxicity of some 
synthetic cannabinoids have led to severe adverse 
effects, including fatalities. Acute synthetic cannabi-
noid intoxications greatly increased in the United 
States between January 2010 and November 
2015.153 Those intoxication events were often con-
fined to specific areas and time periods, and the 
exact synthetic cannabinoids (or combination of 
cannabinoids) causing the intoxications could not 
always be established. For example, cases of exposure 
to synthetic cannabinoids reported to poison centres 
in the Unites States showed a stark but short-lived 
increase in April 2015. The largest increase in acute 
intoxication cases was reported in the north-east 
area of the country, predominantly driven by grow-
ing reports in New York, where an increase in 
cannabinoid-related emergency department visits 
was recorded.154 Among those patient cases, the 
majority (83.1 per cent) were male, with three deaths 
reported. A similar outbreak of intoxications was 
also reported in New York in 2016, when 33 cases 
of AMB-FUBINACA155 intoxications were 
recorded.156 
In addition, several fatal intoxications associated 
with the use of synthetic cannabinoids have been 
reported in Europe. Twenty-nine deaths were asso-
ciated with MDMB-CHMICA, a synthetic 
cannabinoid of a higher potency than THC, and 
potentially also JWH-018,157 in 2014 and 2015.158 
153 Anne M. Riederer and others, “Acute poisonings from syn-
thetic cannabinoids: 50 U.S. toxicology investigators con-
sortium registry sites, 2010-2015”, Morbidity and Mortality 
Weekly Report, vol. 65, No. 27 (2016), pp. 692-695. 
154 Michelle L. Nolan and others, “A public health approach to 
increased synthetic cannabinoid-related morbidity among 
New York City residents, 2014-2015”, International Journal 
of Drug Policy, vol. 34 (2016), pp. 101-103.
155 AMB-FUBINACA (methyl (1-(4-fluorobenzyl)-1H-inda-
zole-3-carbonyl)valinate) is not under international control.
156 Alex J. Adams and others, “‘Zombie’ outbreak caused by 
the synthetic cannabinoid AMB-FUBINACA in New 
York”, New England Journal of Medicine, vol. 376, No. 3 
(2017), pp. 235-242.
157 WHO Expert Committee on Drug Dependence, “MDMB-
CHMICA: critical review report-thirty-eighth meeting” 
(Geneva, World Health Organization, 2016).  
158 EMCDDA, EMCDDA-Europol Joint Report on a New 
Psychoactive Substance: Methyl 2-[[1-(cyclohexylmethyl)
indole-3-carbonyl]amino]-3,3-dimethylbutanoate (MDMB-
CHMICA), Joint Reports Series (Luxembourg, Publications 
Office of the European Union, 2016.
Fig. 20 Exposure to synthetic cannabinoids  
reported to poison centres, United States, 
2012-2016 
Source: American Association of Poison Control Centers.
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in inmates collapsing, seizures and hospitalizations 
from the use of synthetic cannabinoids, despite 
inmates being aware of the potential risks of NPS 
use.162 In addition, the quantities of synthetic can-
nabinoids (973 grams) seized in an English prison 
surveyed during the first three months of 2015 vastly 
outweighed the quantities of cannabis (15 grams) 
and heroin (3 grams) seized.163
In a survey conducted in nine prisons in England 
in the first half of 2016, the self-reported past-
month use of synthetic cannabinoids was reported 
by a third of respondents, with almost half of them 
using the substances daily. Responses implied the 
use of synthetic cannabinoids in acts of bullying in 
which vulnerable mentally ill prisoners were given 
high doses of synthetic cannabinoids for the purpose 
of entertaining others, relieving boredom and 
expressing dominance.164 A study of nine different 
English prisons recorded 54 serious incidents over 
a three-month period (April to June) in 2015 in 
which synthetic cannabinoids were implicated: 44 
per cent of the prisoners involved required hospital 
admission for toxicity, 19 per cent of incidents 
involved violence, and 9 per cent involved 
self-harm.165 
Challenges for legislative responses
The structural diversity and rapid development of 
new derivatives of synthetic cannabinoids pose chal-
lenges to legislative control. A wide range of 
legislative responses have been adopted by Member 
States at the national level to control synthetic can-
nabinoids, including individual listings and generic 
or analogue controls to tackle the increase of new 
compounds. In principle, generic legislation can be 
used to control any group of substances with struc-
tural similarities, which is what has occurred in the 
162 Shane Blackman and Rick Bradley, “From niche to stigma – 
headshops to prison: exploring the rise and fall of synthetic 
cannabinoid use among young adults”, International Journal 
of Drug Policy, vol. 40 (2016), pp. 70-77.
163 Ralphs and others, “Adding spice to the porridge: the devel-
opment of a synthetic cannabinoid market in an English 
prison”.
164 User Voice, “Spice: the bird killer – what prisoners think 
about the use of spice and other legal highs in prison” (May, 
2016).
165 Rehabilitation for Addicted Persons Trust, “Tackling the 
issue of new psychoactive substances in prisons”, RAPt 
Research and Policy Briefing Series No. 4 (London,  
September 2015).
synthetic cannabinoids by inmates. In 2015, syn-
thetic cannabinoids were reported to be particularly 
linked to destabilizing effects in prisons, exacerbat-
ing issues of bullying, debt, riots, self-harm, 
self-inflicted death, serious illnesses and violence 
amongst prisoners and against staff.161 Staff and 
prisoners of a prison in Kent witnessed an increase 
161 United Kingdom, Her Majesty’s Inspectorate of Prisons, 
Changing Patterns of Substance Misuse in Adult Prisons and 
Service Responses (London, 2015).
Use of synthetic cannabinoids in 
prison settings
The use of synthetic cannabinoids seems to be increasing in 
prison settings, probably due to the challenge of detecting and 
identifying them. Up to a third of prisoners in the United King-
dom use synthetic cannabinoids, potentially as a replacement 
for cannabis. Consequently, positive drug tests for cannabis 
have decreased by 59 per cent over the past decade, while 
the detection of synthetic cannabinoids has increased in the 
same period.a In New Zealand in 2015, 60 per cent of police 
detainees had tried synthetic cannabinoids at some point in 
their lives, an increase from the 54 per cent recorded in 2013, 
while 27 per cent had used them in the past 12 months and 12 
per cent had used them in the past month. These proportions 
are relatively high compared to the corresponding prevalence 
of use in the general population, indicating the popularity of 
synthetic cannabinoids among persons who have come into 
formal contact with police.b
A recent report indicated that in the United States, synthetic 
cannabinoids are possibly used by inmates because they are 
not detected in mandatory drug screens or by trained narcotics 
sniffer dogs.c For example, to avoid controls and smuggle the 
substances into correctional facilities, liquid forms of synthetic 
cannabinoids are sprayed onto paper products, such as greet-
ing cards, letters and coffee filters, dried and then mailed 
to inmates, who may then chew or smoke them. A study in 
the United States, which re-tested biological specimens from 
probationers, found metabolites of synthetic cannabinoids in 
samples that originally tested negative for drugs in general tests 
which did not include substances from this group.d Indeed, 
synthetic cannabinoids pose significant challenges not only to 
health care and detection techniques but also to the manage-
ment of offenders in prison settings.
a Kalk and others, “Spice and all things nasty: the challenge of 
synthetic cannabinoids”.
b Wilkins and others, New Zealand Arrestee Drug Use Monitoring 
2010-2015 Report.
c United States, Drug Enforcement Administration, 2016 
National Drug Threat Assessment Summary.
d Wish, Billing and Artigiani, Community Drug Early Warning 
System: The CDEWS-2 Replication Study.
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These NPS with hallucinogenic effects constitute 
roughly 16 per cent (as of December 2016) of all 
substances in the UNODC early warning advisory 
on new psychoactive substances and have been 
reported by 55 Member States.171 These substances 
are chemically diverse and include phenethylamines, 
in particular derivatives of the psychedelic 2C-B 
series of compounds, such as NBOMe compounds, 
and tryptamines (e.g., alpha-methyltryptamine 
(AMT)).172
The emergence of these substances has been associ-
ated with severe intoxications, including fatalities. 
Several countries have reported substances belong-
ing to the NBOMe series that were either sold, or 
referred to, as LSD, “synthetic LSD”173 or “ecstasy”. 
As with LSD, NBOMe compounds are often sold 
on blotter paper which has been soaked with a solu-
tion of the substance. However, users may not be 
aware that they are consuming NBOMe com-
pounds174 and, as NBOMe compounds vary in 
potency and toxicity, even small differences in 
dosage may lead to overdoses with potentially fatal 
consequences.175 
Following their emergence in East Asia, Europe, 
North America and Oceania,176 NBOMe com-
pounds have also been reported in South America. 
The emergence of NPS with hallucinogenic effects 
in South America is noteworthy, as other NPS 
since 1971 (original list, Schedule I of the 1971 Conven-
tion), and 2C-B was placed under international control in 
2001 (Schedule II of the 1971 Convention.
171 UNODC early warning advisory on new psychoactive  
substances.
172 Several NBOMe compounds were placed under interna-
tional control in 2015 (25B-NBOMe, 25C-NBOMe and 
25I-NBOMe). alpha-methyltryptamine (AMT) is not under 
international control. 
173 Will Lawn and others, “The NBOMe hallucinogenic drug 
series: patterns of use, characteristics of users and self-
reported effects in a large international sample”, Journal of 
Psychopharmacology, vol. 28, No. 8 (2014), pp. 780-788.
174 Juji Suzuki and others, “Toxicities associated with NBOMe 
ingestion: a novel class of potent hallucinogens–a review  
of the literature”, Psychosomatics, vol. 56, No. 2 (2015),  
pp. 129-139.
175 “Critical review of psychoactive substances: 25B-NBOMe, 
25C-NBOMe and 25I-NBOMe in WHO Expert Committee 
on Drug Dependence: Thirty‐sixth Report.
176 David M. Wood and others, “Prevalence of use and acute 
toxicity associated with the use of NBOMe drugs”, Clinical 
Toxicology, vol. 53, No. 2 (2015), pp. 85-92; UNODC early 
warning advisory on new psychoactive substances.
case of synthetic cannabinoids as a result of the sheer 
number emerging within a relatively short timeframe 
in some countries. Generic legislation defines a core 
molecular structure and specifies particular varia-
tions of the structure that fall under its control.166 
The intended advantage of generic legislation is the 
simultaneous control of large groups of substances 
without the need to list them individually. This 
includes substances that have not yet been reported, 
potentially preventing their emergence. However, 
the interaction between the generic control of syn-
thetic cannabinoids and market developments has 
proved to be complex.167 In some cases, the defini-
tions of generic legislation have had to be amended 
or extended to include new classes of synthetic can-
nabinoids, whose design was not envisaged under 
the original law.168 Of the 59 countries for which 
information is available on the UNODC early warn-
ing advisory on new psychoactive substances, 19 
countries in Asia, Europe and North America have 
adopted the generic legislation approach. 
B.6. Use of hallucinogenic new  
psychoactive substances is increasing 
in South America 
As a diverse group of both naturally occurring plant-
based and synthetic substances, hallucinogens 
induce distorted states of consciousness, perception, 
thinking and feeling, accompanied by different 
degrees of auditory or visual hallucinations.169 
Synthetic substances, possessing similar effects to 
potent hallucinogens under international control, 
such as LSD and 2C-B, have emerged recently.170 
166 UNODC, “Synthetic cannabinoids: key facts about the 
largest and most dynamic group of NPS”, Global SMART 
Update 2015, vol. 13 (March 2015).
167 Kikura‐Hanajiri and others, “Changes in the prevalence of 
new psychoactive substances before and after the introduc-
tion of the generic scheduling of synthetic cannabinoids in 
Japan”.
168 See, for example, United Kingdom, Misuse of Drugs Act 
1971 (Amendment) Order 2009. A large group of syn-
thetic cannabinoids was first controlled in 2009. Owing to 
new variations of synthetic cannabinoids appearing in the 
market, the generic definition was further revised in 2012. 
However, there are now more “third generation” synthetic 
cannabinoids in the United Kingdom market that do not 
fall under the control of the Misuse of Drugs Act 1971 
(see New Psychoactive Substances Review: Report of the Expert 
Panel (London, September 2014)).
169 Terminology and Information on Drugs (United Nations 
publication, Sales No. E.16.XI.8).
170 (+)-Lysergide (LSD) has been under international control 
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traffickers to sell NPS with hallucinogenic effects. 
Countries in South America have already reacted to 
the emergence of hallucinogenic NPS, including by 
setting up early warning systems, issuing alerts and 
introducing new legislation. For example, the early 
warning system in Colombia, established in 2013, 
issued alerts on NPS sold as LSD that were made 
available online to the general population.181 In 
Chile, meanwhile, a total of 100 NPS, including 
several NBOMe compounds, were included in the 
national lists of controlled psychoactive substances 
in 2014 and 2015.182 A similar approach was 
adopted in Brazil in May 2016, when the Brazilian 
Health Regulatory Agency (ANVISA) approved a 
resolution to add 11 different NBOMe compounds 
to the national list of controlled substances.183 At 
the international level, three NBOMe compounds, 
namely 25B-NBOMe, 25C-NBOMe and 
25I-NBOMe, were placed under international con-
trol in 2015.
B.7. Synthetic opioids: the resurgence 
of fentanyl and its analogues
Synthetic opioids are narcotic analgesics that gen-
erate effects similar to those caused by natural 
opioids. Although some of them have remarkable 
pain-relieving properties and are widely used in 
human therapy, they are also liable to abuse and 
may produce dependence. In North America, the 
non-medical use of synthetic opioids and the use of 
heroin have escalated into a crisis of overdose deaths, 
and evidence of mounting overdoses has been 
re gistered in other regions (for more information, 
see booklet 2 of the present report).
The growing supply and use of illicitly manufactured 
synthetic opioids such as fentanyl and fentanyl ana-
logues is particularly alarming and present a complex 
challenge. Fentanyl itself is a powerful analgesic with 
181 UNODC, “Global SMART programme Latin America”, 
Information Bulletin No.º 2 (September 2016).
182 Chile, Ministry of the Interior and Public Security, Offi-
cial Journal of the Republic of Chile, No. 41120 (Santiago, 
30 March 2015); and Chile, Ministry of the Interior and 
Public Security, National Committee on New Psychoactive 
Substances, Inter-agency coordination, collection and analy-
sis of available information to update drug lists”, Report 
No. 1 (Santiago, September 2015), pp. 5-9.
183 Brazil, Brazilian Health Regulatory Agency, Resolution No. 
79 (23 May 2016).
groups, such as synthetic cannabinoids, are much 
less prominent in that subregion than in North 
America or Europe. An explanation for this regional 
peculiarity could be that hallucinogenic NPS are 
emerging onto an existing and possibly growing 
market for hallucinogens such as LSD. Indeed, sei-
zures of NBOMe compounds have increased in 
South America and recent surveys show increases 
in the prevalence of use of LSD. In Chile, several 
NBOMe compounds sold as LSD were seized by 
law enforcement authorities or identified in con-
nection with emergency room admissions.177 
Moreover, in Chile, the past-year prevalence of use 
of LSD among the general population increased 
from 0.2 per cent in 2012 to 0.5 per cent in 2014. 
By comparison, the number of doses of NBOMe 
compounds seized in Chile increased exponentially, 
from 2,245 in 2013 to 41,762 in 2015.178
In Colombia, there was a significant increase in the 
lifetime prevalence of LSD use among the general 
population, from 0.05 per cent in 2008 to 0.73 per 
cent in 2013,179 similar to the trend in Chile. How-
ever, a number of emergency room cases documented 
that users, wrongly believing to have consumed 
LSD, had actually taken 25B-NBOMe and 
25C-NBOMe. Similarly, shipments of “ecstasy” and 
“LSD” containing NPS have been reported being 
sent from Western and Central Europe to South 
America. In 2013, the National Police of Chile 
seized a shipment of 800 stamps, originating in 
Spain, that supposedly contained LSD but which 
actually consisted of 25I-NBOMe.180 Given the 
presence of hallucinogenic NPS in South America, 
documented in seizure data and emergency room 
reports, it is possible that a potentially growing 
market for hallucinogens, indicated by increases in 
prevalence of use, has opened up opportunities for 
177 UNODC, “Global SMART programme Latin America”, 
Information Bulletin No. 1 (June 2016).
178 Chile, Ministry of the Interior and Public Security, “NSP y 
precursors”, pp. 14-16; (Spanish only) available from www.
interior.gob.cl.
179 Observatorio de Drogas de Colombia, Estudio Nacional 
de Consumo de Sustancias Psicoactivas en Colombia—2013 
(Bogotá, June 2014). Additional information to the final 
report, drawn from the database of the study, available from 
www.unodc.org.
180 Inter-American Drug Abuse Control Commission of the 
Organization of American States, Report on Drug Use in the 
Americas, 2015, p. 154.
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is intended only for veterinary use on large animals 
and is not approved for human use.188 
Synthetic opioids have a well-documented potential 
for abuse and dependence, which is reflected in 
international legislative responses. First synthesized 
in 1959, fentanyl was placed under international 
control as a Schedule I substance in 1964 under the 
Single Convention on Narcotic Drugs of 1961. In 
the ensuing decades, the list of scheduled substances 
grew to include all fentanyl analogues approved for 
medical use in humans, and several analogues that 
were not developed into pharmaceutical products 
were placed under international control between 
1988 and 1990.189 More recently, acetylfentanyl 
and butyrfentanyl were placed under international 
control.190 Carfentanil, which was first synthesized 
in 1974 and remains the most potent commercially 
available opioid in the world, is not under interna-
tional control.
Within the past five years, more than a dozen addi-
tional synthetic opioids have entered the illicit 
opioid market, some of which have been rediscov-
ered by traffickers in research done between the 
1960s and 1990s, when they were described in sci-
entific literature but never developed into 
pharmaceutical products. Examples include several 
fentanyl analogues developed between the 1960s 
and 1990s, such as acetylfentanyl, butyrfentanyl, 
furanylfentanyl and ocfentanil.191 Novel fentanyl 
analogues such as acrylfentanyl and para-fluoroisobu-
tyrfentanyl continue to appear.192 A number of 
newly marketed synthetic opioids have structures 
distinct from those used in medical practice, includ-
ing AH-7921 (a benzoamide), MT-45 (a piperazine) 
and U-47700 (a compound closely related to 
AH-7921), all of which were first synthesized in the 
188 P. A. J. Janssen, “Potent, new analgesics, tailor-made for 
different purposes”, Acta Anaesthesiologica Scandinavica, vol. 
26, No. 3 (June 1982), pp. 262-268.
189 UNODC, “Fentanyl and its analogues: 50 years on”, Global 
SMART Update 2017, vol. 17 (Vienna, March 2017).
190 Acetylfentanyl was placed under international control in 
2016 (Schedules I and IV of the 1961 Convention) and 
butyrfentanyl in 2017 (Schedule I of the 1961 Conven-
tion). 
191 Furanylfentanyl and ocfentanil are not under international 
control. 
192 Acrylfentanyl and para-fluoroisobutyrfentanyl are not under 
international control. 
an established place in medicine, but it is also known 
for its potential for abuse and dependence. Heroin 
containing, or substituted with, fentanyl or fentanyl 
analogues originally appeared on the illicit drug 
market in the 1970s and 1980s under names like 
“China White”, “Tango and Cash” or “synthetic 
heroin”, products that became notorious for acci-
dental overdoses.184 A similar situation seems to 
have been developing since around 2014, when fen-
tanyl originating mainly from clandestine 
manufacturing rather than from diversion of phar-
maceutical products containing fentanyl was 
identified on the opioid market. That situation has 
been aggravated by the rapid appearance of novel 
fentanyl analogues and other synthetic opioids that 
have not been approved for medical use. In recent 
years, several emergent opioids have been associated 
with increasing numbers of serious adverse events 
and deaths.185 The pills and powders containing 
synthetic opioids sold on the illicit market pose a 
threat to public health because of the variable quan-
tity and potency of their active components, which 
in extreme cases, such as carfentanil,186 may be 
10,000 times more potent than morphine. Such 
products can prove particularly dangerous when 
sold as street heroin or as counterfeit prescription 
drugs without the user’s knowledge.
Medical use and adverse effects of  
synthetic opioids
Fentanyl, which has about 100 times the potency 
of morphine, is the strongest opioid available for 
use in humans. Its powerful analgesic and sedative 
effects mean that it is widely used in the management 
of severe pain and in anaesthesia. The three fentanyl 
analogues approved for pharmaceutical use, 
sufentanil, alfentanil and remifentanil,187 have very 
short onset and duration of action, and their medical 
use is limited to intravenous anesthesia. Carfentanil 
184 G.L. Henderson, “Fentanyl-related deaths: demograph-
ics, circumstances, and toxicology of 112 cases”, Journal of 
Forensic Sciences, vol. 36, No. 2 (March 1991), pp. 422-
433.
185 UNODC early warning advisory on new psychoactive sub-
stances, “Deaths associated with use of emerging synthetic 
opioids”, November 2016. Available at www.unodc.org.
186 Carfentanil is not under international control. 
187 Sufentanil, alfentanil and remifentanil have been under 
international control since 1980, 1984 and 1999, respec-
tively, and are listed in Schedule I of the 1961 Convention. 
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experimenting with new synthetic opioids, whose 
levels of potency are not well-defined, increase the 
odds of making a fatal mistake.
An overdose can also be caused by handling strong 
synthetic opioids without the precautions that pre-
vent the substance from being inhaled or absorbed 
through the skin or mucous membranes. Contact 
with fentanyl or its analogues is so hazardous that 
both Canada and the United States have recorded 
incidents of hospitalization of law enforcement offic-
ers who carried out seizures of such chemicals. The 
Drug Enforcement Administration of the United 
States has recently released safety alerts for fentanyl 
and carfentanil, advising what steps to follow in 
situations where such drugs might be present, 
including the immediate application of naloxone in 
case of exposure.198 
Manufacturing and trafficking of  
synthetic opioids
According to the Drug Enforcement Administra-
tion, the current fentanyl crisis in the United States 
is largely fuelled by illicitly manufactured fentanyl 
and its analogues,199 which are either illegally 
imported as such or synthesized from imported pre-
cursors. The materials and apparatus used in fentanyl 
synthesis and tableting are inexpensive and easy to 
obtain from online vendors, and the synthesis does 
not require sophisticated laboratory skills, which 
facilitates small-scale manufacturing by minor drug 
trafficking organizations. Most of the fentanyl 
recently seized in the United States has been of non-
pharmaceutical origin and synthesized using the 
so-called “Siegfried route”, which was first described 
in the 1980s and is relatively easy to perform.
Precursor chemicals used in this route are N-phene-
thyl-4-piperidone (NPP) or its derivative, 
4-anilino-N-phenethylpiperidine (ANPP). The 
majority of fentanyl analogues reported to UNODC 
in recent years, including acetylfentanyl, butyrfen-
tanyl and furanylfentanyl, can be synthesized from 
198 US Drug Enforcement Administration, DEA Officer Safety 
Alert, Fentanyl – A Real Threat to Law Enforcement. Avail-
able at www.dea.gov/video_clips/Fentanyl%20Roll%20
Call%20Video.mp4.
199 United States, Drug Enforcement Administration, “Coun-
terfeit prescription pills containing fentanyls: a global 
threat”. DEA Intelligence Brief. DEA-DCT-DIB-021-16 
(2016).
1970s.193 Fourteen fentanyl analogues and three 
synthetic opioids belonging to other structural 
groups were reported to the UNODC early warn-
ing advisory on new psychoactive substances 
between 2012 and 2016 by countries in East Asia, 
Europe and North America. The countless possibili-
ties for creating new compounds by making minor 
changes in chemical structures pose a growing chal-
lenge to legislative controls.  
Risks associated with the use of,  
or exposure to, synthetic opioids
The non-medical use of synthetic opioids can have 
severe health consequences. Tolerance and depend-
ence develop very quickly and may reach extreme 
levels. Above all, each episode of non-medical use 
carries a high risk of overdose and death as a result 
of respiratory depression, a common side effect of 
opioids. Overdoses can be effectively reversed by 
naloxone, a µ-opioid receptor antagonist but, impor-
tantly, reversing overdoses of fentanyl or its analogues 
often requires very high doses of naloxone. In 
response to the growing need for overdose treatment, 
some countries have made efforts to increase the 
availability of naloxone, including Australia,194 
Canada,195 Italy196 and the United States.197
The recreational use of pharmaceutical products 
containing fentanyl can easily prove fatal if users 
increase the dose or change the route of administra-
tion. The use of illicitly manufactured synthetic 
opioids increases the danger because they lack qual-
ity control, are typically not portioned in precise 
doses and can be deadly in minuscule amounts 
because of their extreme potency. Users 
193 AH-7921, MT-45 and U-47700 have been under inter-
national control since 2015, 2016 and 2017, respectively, 
listed in Schedule 1 of the 1961 Convention.
194 Australia, Department of Health, Therapeutic Goods 
Administration, “Final decisions and reasons for decisions 
by a delegate of the Secretary to the Department of Health” 
(Canberra, 2015).
195 Canada, Health Canada, “Availability of Naloxone Hydro-
chloride Nasal Spray (NARCAN®) in Canada”, 6 July 2016. 
Available from www.hc-sc.gc.ca. 
196 Simon R. Lenton and Kim M. Hargreaves, “Should we 
conduct a trial of distributing naloxone to heroin users for 
peer administration to prevent fatal overdose?” Medical 
Journal of Australia, vol. 173, No. 5 (September 2000), pp. 
260-263. 
197 US Department of Health and Human Services, The 
Opioid Epidemic: By the Numbers, June 2016.
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main synthetic opioid liable to non-medical use. In 
Estonia, clandestinely produced fentanyl or its ana-
logues are sold as the drug of choice.
Owing to their extreme potencies, synthetic opioids 
are often present in trace amounts in the products 
available, be it as pharmaceuticals, illicitly manu-
factured material or in admixture with, for example, 
heroin. This makes detection of these substances 
extremely challenging in the forensic laboratory and 
could lead to underreporting of the extent to which 
they appear on the market.
B.8. GBL: a ready source of GHB?
Gamma-hydroxybutyrate (GHB) is used in medicine 
as an adjunct in surgical anaesthesia and as an aid 
in alcohol or opiate withdrawal. The depressant 
effect of GHB on the central nervous system pro-
duces relaxation, reduced inhibition, euphoria and 
mild hallucinations — factors that have driven the 
recreational use of the substance. On the illicit drugs 
market, GHB is known under street names such as 
“G”, “liquid ecstasy”, “Georgia Home Boy” and 
“Grievous Bodily Harm” and has been associated 
with drug-facilitated sexual assault.201 Chronic use 
of GHB, which was placed under international con-
trol in 2001, results in the development of 
physiological and physical dependence and with-
drawal syndromes. GHB is particularly dangerous 
when ingested together with alcohol or other seda-
tives, and overdosing on GHB can lead to coma, 
respiratory depression and death. 
GHB has been implicated in a rising number of 
fatalities, particularly in developed subregions, 
including North America, Western and Central 
Europe and Australasia. A recent European study 
found that GHB was ranked as the fourth most 
commonly reported drug for hospital emergency 
cases and was on an upward trend.202 In 2015, a 
substantial increase in deaths associated with GHB 
was registered in London, of which 25 per cent of 
case history records indicated an association with 
201 See also Guidelines for the Forensic Analysis of Drugs Facili-
tating Sexual Assault and Other Criminal Acts (ST/NAR/45).
202 EMCDDA, Hospital Emergency Presentations and Acute 
Drug Toxicity in Europe: Update from the Euro-DEN Plus 
Research Group and the EMCDDA, Rapid Comunication 
Series (Luxembourg, Publications Office of the European 
Union, August 2016). 
NPP or ANPP. These two precursors were placed 
under international control in March 2017. How-
ever, a large group of long-known fentanyl analogues 
that were put under international control between 
the 1960s and the 1990s, and which do not appear 
to be linked to the current opioid crisis in the United 
States, cannot be produced from NPP or ANPP.
Data reported to UNODC on dismantled labora-
tories that had been used for manufacturing fentanyl 
include three cases in Canada (one kitchen labora-
tory and one industrial-scale facility in 2011, and 
one medium-to-large-scale facility in 2012), one 
kitchen laboratory in Germany (2015), one kitchen 
laboratory in Slovakia (2011), one case of manufac-
turing 3-methylfentanyl200 in the Russian Federation 
(2014) and three kitchen laboratories in the United 
States (one in 2013 and two in 2015).
Sources of synthetic opioids sold on illicit markets 
are often specific to a given subregion or country. 
In North America, for example, synthetic opioids 
are most commonly sold as adulterated/substituted 
heroin or counterfeit pharmaceuticals resembling 
prescription pills. In Australia and Germany, fenta-
nyl diverted from pharmaceutical products is the 
200 3-Methylfentanyl was placed under international control in 
1988 (in Schedules I and IV of the 1961 Convention). 
Fig. 21 Annual number of synthetic opioids 
reported to UNODC, 2012-2016 
Source: UNODC early warning advisory on new psychoactive 
substances. Includes only synthetic opioids reported as NPS 
(i.e., with no current approved medical use). Data for 2016 
are preliminary. 
0
2
4
6
8
10
12
20
12
20
13
20
14
20
15
20
16
Other synthetic opioids
Fentanyl analogues
50
W
O
RL
D
 D
R
U
G
 R
EP
O
RT
 2
01
7
America, in countries where GBL is under national 
control, significant amounts of GBL were seized 
from January 2015 to December 2016, including 
several shipments exceeding 100 kg and one excep-
tionally large seizure of 15 tons of GBL in Poland 
in March 2016, which was destined for the Neth-
erlands. Ordering such large amounts, breaking 
them down into smaller shipments and successfully 
distributing them requires a certain degree of organi-
zation and a correspondingly large consumer base. 
Indeed, a 2013 study combining Internet-monitor-
ing processes, packaging and isotopic analyses 
concluded that the GBL market was organized into 
three levels: a manufacturing stage located mainly 
in China and Germany; an intermediary online dis-
tribution level hosted mainly in the Netherlands; 
and customers who order online.207
In view of the large-scale shipments of GBL seized 
in 2015 and 2016, it seems plausible that organized 
criminal groups are trying to increase the availability 
of GBL. However, because of the rapid conversion 
of GBL to GHB upon ingestion, it is challenging, 
from the forensic perspective, to determine from 
human fluids which of the two substances was 
ingested initially. It thus remains uncertain to what 
extent GBL is used as a precursor for GHB or con-
sumed directly. 
B.9. Ketamine supply is increasing in 
South-East Asia
A widely used human and veterinary anaesthetic, 
ketamine is listed as an essential medicine by the 
World Health Organization (WHO).208 Increasing 
presence on illicit drug markets led to the schedul-
ing of ketamine as a controlled substance in 70 out 
of 100 countries209 that responded to a WHO 
survey in 2015. For non-medical use, ketamine is 
typically presented in the form of a powder, although 
it may be available as pills, and is sold on illicit 
207 Diego Pazos and others, “Combining Internet monitoring 
processes, packaging and isotopic analyses to determine the 
market structure: example of gamma butyrolactone”, Foren-
sic Science International, vol. 230, Nos. 1-3 (2013),  
pp. 29-36.
208 WHO, Model List of Essential Medicines: 19th List (April 
2015) (amended November 2015). 
209 “Ketamine (INN): questionnaire report”, presented to 
the WHO Expert Committee on Drug Dependence at 
its thirty-seventh meeting, held in Geneva from 16 to 20 
November 2015. 
so-called “chemsex” events.203 However, fatal cases 
are likely to be underreported because the drug is 
often not included in a routine analysis and has a 
short half-life, which limits toxicological detection. 
While GHB is controlled under the 1971 
Convention, the closely related chemical gamma-
butyrolactone (GBL),204 which is an important 
solvent and reagent in industry, is not under 
international control. GBL has widespread legitimate 
use in industry, with global requirements being in 
the region of hundreds of thousands of tons and 
single consignments reaching up to 500 tons.205 
GBL also serves as a prodrug of GHB, being readily 
converted to the latter after ingestion and producing 
the full spectrum of effects. Furthermore, GBL 
provides a ready source as an immediate precursor 
for the clandestine manufacture of GHB.
It is difficult to assess to what extent GBL is traded 
for non-industrial purposes such as direct human 
consumption or illicit conversion to GHB. However, 
recent reports by EMCDDA and Europol about the 
European GBL market indicate that large-scale man-
ufacturing for the drug market seems to be 
concentrated in the Netherlands, and it occasionally 
occurs in the same place as the manufacturing of 
other illicitly used synthetic drugs such as MDMA 
or amphetamine.206 This provides a link between 
GBL and the clandestine manufacture and traffick-
ing of illicit drugs. 
The use of GBL as a prodrug for GHB may actually 
be more prevalent than assumed, with small-scale 
studies indicating that users may be mistakenly self-
reporting ingestion of GHB when they have in fact 
ingested GBL. In Europe, Oceania and North 
203  Joanna Hockenhull, Kevin G. Murphy and Sue Paterson, 
“An observed rise in γ-hydroxybutyrate-associated deaths in 
London: evidence to suggest a possible link with concomi-
tant rise in chemsex”, Forensic Science International, vol. 
270, No. 1 (January 2017), pp. 93-97. 
204 Another substance closely related to GHB is 1,4-butanediol 
(1,4-BD; BDO), a substance widely used in industry. It 
can be easily converted into GHB by chemical synthesis 
or, in principle, also in the human body. However, direct 
consumption of 1,4-BD for recreational purposes is rarely 
reported. 1,4-BD is not under international control.
205 “Critical review of psychoactive substances: gamma-butyro-
lactone (GBL)” in WHO Expert Committee on Drug Depen-
dence: Thirty‐sixth Report.
206 EMCDDA and Europol, EU Drug Markets Report: In-Depth 
Analysis.
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pharmaceutical sector, clandestine manufacture has 
emerged in recent years as a significant source, 
particularly in East and South-East Asia. In China, 
89 illicit ketamine laboratories were dismantled in 
2014 and 118 in 2013, while in Malaysia, national 
authorities dismantled the first ever ketamine 
manufacturing facility in the country in 2016. Other 
countries that have reported ketamine labs since 
2010 include Canada (1 in 2013), India (1 in 2012) 
and the United States (1 in 2013). 
The average number of countries/territories report-
ing ketamine seizures increased from 21 over the 
period 2010-2012, to 27 over the period 2013-
2015. In addition, significant increases in the 
quantities of ketamine seized globally have been 
reported since 2012, which have mainly been driven 
by increases in seizures in China. In 2015, global 
ketamine seizures amounted to 23 tons, the largest 
amount recorded since the start of systematic moni-
toring by UNODC in 1999.
The proportion of ketamine seized in different sub-
regions has varied considerably since 2010. East and 
South-East Asia accounted for 65 per cent of the 
amount seized globally in 2010, while Europe and 
South Asia accounted for 6 per cent (800 kg) and 
10 per cent (1 ton) respectively. By 2015, East and 
markets under different street names such as “K” 
and as established products such as “ecstasy” or 
methamphetamine pills (Thailand, Indonesia),210 
sometimes to unwitting users. In 2014, China 
requested consideration for the scheduling of keta-
mine under the international drug control 
conventions to curb its abuse,211 but WHO recom-
mended against international control of ketamine 
on the basis that this might affect its availability for 
medical use.212 
In a 2015 WHO survey, the use of ketamine for 
non-medical purposes was reported by 32 countries, 
of which 10 identified specific subpopulations that 
use ketamine: youth, males (aged 16-24 years), 
prison population, medical staff, night clubbers, 
pub or party goers and recreational drug users.213 
The non-medical use of ketamine is indicated to 
have increased in each of the past six years in (main-
land) China but seems to be on decline in Hong 
Kong, China, where — based on drug-user registra-
tion data — the number of reported ketamine users 
decreased by 46 per cent over the past five years, 
from 3,600 in 2011 to 1,974 in 2015. In the United 
States, past-year use among twelfth graders remained 
without significant year-on-year changes over the 
period 2013 and 2016, ranging between 1.2 per 
cent and 1.5 per cent.214 In England and Wales, 
after a peak in 2010/11, the past-year prevalence of 
use of ketamine seemed to be on the decrease, with 
2015/16 drug-use survey prevalence figures back to 
the baseline levels first recorded in 2006/07.215 
While the ketamine sold on drug markets in the 
past tended to have been diverted from the 
210 APAIC, Synthetic drug trends, National trends: Indonesia 
(1 December 2014) and Thailand (14 February 2017). 
Available at www.apaic.org.
211 Note by the Secretariat on the changes in the scope of con-
trol of substances (E/CN.7/2015/7).
212 WHO Expert Committee on Drug Dependence Thirty-seventh 
Report, WHO Technical Report Series, No. 998 (Geneva, 
World Health Organization, 2015). 
213 “Ketamine (INN): questionnaire report”, presented to 
the WHO Expert Committee on Drug Dependence at its 
thirty-seventh meeting. 
214 United States, National Institute on Drug Abuse, “Monitor-
ing the future study: trends in prevalence of various drugs”. 
Available at www.drugabuse.gov. 
215 Ketamine was first controlled in the United Kingdom as 
a class C drug in 2006, and moved to the stricter class B 
schedule in 2014. 
Fig. 22 Prevalence of use of ketamine in 
England and Wales, United Kingdom, 
2006/07-2015/16
Source: Home Office of the United Kingdom, “Drug misuse: 
findings from the 2015 to 2016 CSEW”, data tables, 2nd  
edition. 
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South-East Asia accounted for 97 per cent of the 
total quantity of ketamine seized worldwide that 
year, which took place primarily in China (19.6 
tons), including Taiwan Province of China (1.8 tons) 
and Hong Kong, China (0.5 tons). 
The amount of ketamine seized in East and South-
East Asia is also significant in comparison with that 
of other major drugs of abuse in the subregion. For 
example, the quantity of ketamine seized in 2015 
was twice that of heroin (11 tons). 
While ketamine manufactured in clandestine labo-
ratories in mainland China is believed to mainly be 
consumed locally, there is trafficking to the Macao, 
China; Hong Kong, China; and other countries. 
Hong Kong, China, was perceived to be a trans-
shipment location for ketamine from mainland 
China en route to other countries.216
216 APAIC, Synthetic drug trends, National trends: Hong 
Kong, China, and Thailand, 14 February 2017.
Fig. 23 Quantities of ketamine seized globally, 
2010-2015
Source: UNODC, responses to annual report questionnaire, 
2010-2015. 
Fig. 24 Proportion of quantity of ketamine 
seized, by subregion/region, 2010-
2015
Source: UNODC, responses to annual report questionnaire, 
2010-2015. 
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GLOSSARY  
amphetamine-type stimulants — a group of sub-
stances composed of synthetic stimulants that were 
placed under international control in the Conven-
tion on Psychotropic Substances of 1971 and are 
from the group of substances called amphetamines, 
which includes amphetamine, methamphetamine, 
methcathinone and the “ecstasy”-group substances 
(3,4-methylenedioxymethamphetamine (MDMA) 
and its analogues).
amphetamines — a group of amphetamine-type 
stimulants that includes amphetamine and 
methamphetamine.
annual prevalence — the total number of people of 
a given age range who have used a given drug at 
least once in the past year, divided by the number 
of people of the given age range, and expressed as a 
percentage.
coca paste (or coca base) — an extract of the leaves 
of the coca bush. Purification of coca paste yields 
cocaine (base and hydrochloride).
“crack” cocaine — cocaine base obtained from 
cocaine hydrochloride through conversion processes 
to make it suitable for smoking.
cocaine salt — cocaine hydrochloride.
new psychoactive substances — substances of abuse, 
either in a pure form or a preparation, that are not 
controlled under the Single Convention on Narcotic 
Drugs of 1961 or the 1971 Convention, but that 
may pose a public health threat. In this context, the 
term “new” does not necessarily refer to new inven-
tions but to substances that have recently become 
available.
opiates — a subset of opioids comprising the various 
products derived from the opium poppy plant, 
including opium, morphine and heroin.
opioids — a generic term applied to alkaloids from 
opium poppy (opiates), their synthetic analogues 
(mainly prescription or pharmaceutical opioids) and 
compounds synthesized in the body.
problem drug users — people who engage in the 
high-risk consumption of drugs; for example, people 
who inject drugs, people who use drugs on a daily 
basis and/or people diagnosed with drug use disor-
ders (harmful use or drug dependence), based on 
clinical criteria as contained in the Diagnostic and 
Statistical Manual of Mental Disorders (fifth edi-
tion) of the American Psychiatric Association, or 
the International Classification of Diseases (tenth 
revision) of the World Health Organization. 
people who suffer from drug use disorders/people with 
drug use disorders — a subset of people who use 
drugs. People with drug use disorders need treat-
ment, health and social care and rehabilitation. 
Dependence is a drug use disorder. 
prevention of drug use and treatment of drug use dis-
orders — the aim of “prevention of drug use” is to 
prevent or delay the initiation of drug use, as well 
as the transition to drug use disorders. Once there 
is a drug use disorder, treatment, care and rehabili-
tation are needed.
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REGIONAL GROUPINGS
• Central Asia and Transcaucasia: Armenia, 
Azerbaijan, Georgia, Kazakhstan, Kyrgyzstan, 
Tajikistan, Turkmenistan and Uzbekistan
• East and South-East Asia: Brunei Darussalam, 
Cambodia, China, Democratic People’s 
Republic of Korea, Indonesia, Japan, Lao 
People’s Democratic Republic, Malaysia, 
Mongolia, Myanmar, Philippines, Republic of 
Korea, Singapore, Thailand, Timor-Leste and 
Viet Nam 
• South-West Asia: Afghanistan, Iran (Islamic 
Republic of ) and Pakistan 
• Near and Middle East: Bahrain, Iraq, Israel, 
Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi 
Arabia, State of Palestine, Syrian Arab Republic, 
United Arab Emirates and Yemen
• South Asia: Bangladesh, Bhutan, India, 
Maldives, Nepal and Sri Lanka 
• Eastern Europe: Belarus, Republic of Moldova, 
Russian Federation and Ukraine
• South-Eastern Europe: Albania, Bosnia and 
Herzegovina, Bulgaria, Croatia, Montenegro, 
Romania, Serbia, the former Yugoslav Republic 
of Macedonia and Turkey
• Western and Central Europe: Andorra, Austria, 
Belgium, Cyprus, Czechia, Denmark, Estonia, 
Finland, France, Germany, Greece, Hungary, 
Iceland, Ireland, Italy, Latvia, Liechtenstein, 
Lithuania, Luxembourg, Malta, Monaco, 
Netherlands, Norway, Poland, Portugal, San 
Marino, Slovakia, Slovenia, Spain, Sweden, 
Switzerland and United Kingdom of Great 
Britain and Northern Ireland
• Oceania: Australia, Fiji, Kiribati, Marshall 
Islands, Micronesia (Federated States of ), 
Nauru, New Zealand, Palau, Papua New 
Guinea, Samoa, Solomon Islands, Tonga, 
Tuvalu, Vanuatu and small island territories
The World Drug Report uses a number of regional 
and subregional designations. These are not official 
designations, and are defined as follows:
• East Africa: Burundi, Comoros, Djibouti, 
Eritrea, Ethiopia, Kenya, Madagascar, 
Mauritius, Rwanda, Seychelles, Somalia, 
Uganda and United Republic of Tanzania 
• North Africa: Algeria, Egypt, Libya, Morocco, 
South Sudan, Sudan and Tunisia
• Southern Africa: Angola, Botswana, Lesotho, 
Malawi, Mozambique, Namibia, South Africa, 
Swaziland, Zambia and Zimbabwe
• West and Central Africa: Benin, Burkina Faso, 
Cameroon, Cabo Verde, Central African 
Republic, Chad, Congo, Côte d’Ivoire, 
Democratic Republic of the Congo, Equatorial 
Guinea, Gabon, Gambia, Ghana, Guinea, 
Guinea-Bissau, Liberia, Mali, Mauritania, 
Niger, Nigeria, Sao Tome and Principe, Senegal, 
Sierra Leone and Togo 
• Caribbean: Antigua and Barbuda, Bahamas, 
Barbados, Bermuda, Cuba, Dominica, 
Dominican Republic, Grenada, Haiti, Jamaica, 
Saint Kitts and Nevis, Saint Lucia, Saint 
Vincent and the Grenadines and Trinidad and 
Tobago
• Central America: Belize, Costa Rica,  
El Salvador, Guatemala, Honduras, Nicaragua 
and Panama
• North America: Canada, Mexico and United 
States of America 
• South America: Argentina, Bolivia 
(Plurinational State of ), Brazil, Chile, 
Colombia, Ecuador, Guyana, Paraguay, Peru, 
Suriname, Uruguay and Venezuela (Bolivarian 
Republic of )
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To celebrate 20 years since its inception, the World Drug 
Report 2017 is presented in a new five-booklet format 
designed to improve reader friendliness while maintaining the 
wealth of information contained within. 
Booklet 1 summarizes the content of the four subsequent 
substantive booklets and presents policy implications drawn 
from their findings. Booklet 2 deals with the supply, use and 
health consequences of drugs. Booklet 3 focuses on the 
cultivation, production and consumption of the three 
plant-based drugs (cocaine, opiates and cannabis) and on the 
impact of new cannabis policies. Booklet 4 provides an 
extended analysis of the global synthetic drugs market and 
contains the bulk of the analysis for the triennial global 
synthetic drugs assessment. Finally, Booklet 5 contains a 
discussion on the nexus between the drug problem, organized 
crime, illicit financial flows, corruption and terrorism.
 
Enhanced by this new format, the World Drug Report 2017 is, 
as ever, aimed at improving the understanding of the world 
drug problem and contributing towards fostering greater 
international cooperation for countering its impact on health 
and security.
The statistical annex is published on the UNODC website: 
www.unodc.org/wdr/2017
